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ABSTRACT 
 
ALICIA ANN MIDLAND: Characterization of the breast cancer kinome 
(Under the direction of Shawn M. Gomez and Gary L. Johnson) 
 
Protein kinases are integral to cellular signaling and their dysfunction can lead to 
the development of cancer. Breast cancer is a heterogeneous disease that is responsible 
for many deaths each year where abnormalities in kinases have been observed. Many 
studies focus on a select few kinases and the interaction of all 518 kinases is not well 
understood. Wide-scale molecular profiling of kinases, including signature-finding and 
network reconstruction, is a necessary step towards understanding how these genes get 
deregulated and progress in disease.  
High-throughput analysis techniques were applied to quantify the expression of 
protein kinases in various types of breast cancer including: cell lines, mouse models, and 
a patient tumor. Using RNA-seq, we analyzed the expression of over 70% of kinases in 
each breast cancer cell type. An emerging technique that combines the use of multiplexed 
inhibitor beads with mass spectrometry (MIB/MS) was used to measure kinase activity 
changes upon treatment with kinase inhibitors. MIB/MS found 40-50% of the RNA-seq 
expressed kinases to be active. Statistical pattern recognition and multivariate methods 
were tested to find possible kinase activity signatures for breast cancer subtypes. We also 
constructed simple networks for triple negative breast cancer (TNBC) samples using 
correlation calculations of MIB/MS data across drug treatments. We found that many of 
the kinase outliers and nodes overlapped with a previously determined kinase signature 
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for a reprogrammed TNBC kinome, but the lack of experimental replicates disallows us 
from making statistically significant predictions from the data.  
Dealing with high-throughput experiments made us realize that organization of 
the generated data is another important challenge. Data should be made openly available 
because someone else may find unique characteristics or results that were initially 
missed. We developed Kinome DB, a protein kinase website that compiles information 
directly related to kinase experiments.   
While we were unable to draw concrete conclusions regarding kinase activity 
signatures, we tested the viability of several methods to evaluate MIB/MS data and 
characterized the breast cancer kinase transcriptome using RNA-seq. These are necessary 
steps for determining new kinase drug targets and rational combination therapies for 
treating breast cancer. 
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Breast cancer is collectively the second most frequent cause of death in women 
and the chance of a woman developing breast cancer in her lifetime is approximately 1 in 
8 (American Cancer Society, 2012). The disease is heterogeneous, with known 
differences in molecular variations, histological composition, and clinical outcomes. 
Breast cancers are typically diagnosed based on the presence/absence of three receptors: 
estrogen receptors (ER), progesterone receptors (PR), and v-erb-b2 erythroblastic 
leukemia viral oncogene homolog 2 (HER2/neu). Triple-negative breast cancer (TNBC) 
is a particularly aggressive and commonly reoccurring breast cancer subtype that does not 
express the common hormone receptor targets (ER-/PR-/HER2/neu-).  
Studies of the breast cancer genome have divided tumors into five subtypes 
(Luminal A, Luminal B, HER2-enriched, Basal-like, and Claudin-low) as well as a 
normal-like group (Herschkowitz et al., 2007; Perou et al., 2000; Sørlie et al., 2001, 
2003). Profiling of microarray gene expression data was used to determine these subtypes 
and the subtypes have been found to predict patient outcomes (van  ’t Veer et al., 2002). 
Despite these advances, there are many unanswered questions regarding molecular 
changes in breast cancer, why drug treatments are or become ineffective, and what we 
should target to stop or treat the disease. To address these questions, this dissertation 
focuses on incorporating different data types to computationally explore protein kinases 
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in breast cancer, mainly in TNBC, which is the most difficult to treat, and how to 
organize large datasets, enabling researchers to acquire meaningful information from 
them. 
 
Importance of Protein Kinases in Cancer 
Protein kinases are key components of cellular signal transduction pathways and 
their abnormal regulation or overexpression is fundamental to cancer development and 
progression. The human kinome is made up of approximately 518 kinases. Many protein 
kinase inhibitors are administered clinically to treat cancers, but with limited success 
because tumors are able to evade the treatment. For example, through the activation of 
alternative kinase-regulated pathways. Much is still unknown about the network 
dynamics of kinases and how the kinome changes in response to cancer and cancer 
treatments. 
Protein kinase genes are commonly mutated in cancer. Driver mutations give 
cancer cells a selective advantage for growth and are causally associated in oncogenesis 
(Stratton, Campbell, & Futreal, 2009). The Sanger Institute examined the protein coding 
sequence of 518 protein kinase genes in primary cancers and cancer cell lines using 
Affymetrix SNP microarrays and their screen of 25 breast cancers detected 92 mutations 
(Stephens et al., 2005). Mutations were found in approximately 15% of kinases and a 
majority were base substitutions that resulted in missense amino acids (Stephens et al., 
2005). A recent genomic sequencing study of 100 breast cancer tumors found 40 driver 
mutations with many in kinases or kinase related pathways (Stephens et al., 2012). 
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Since there are over 100 kinase-specific inhibitors in Phase 1-3 clinical trials for 
various diseases, kinases are a viable group to target for new breast cancer, specifically 
TNBC, treatment therapies (Walker & Newell, 2009). The kinase inhibitors are effective 
for treating patients who have a specific set of mutations in kinase genes, but not for 
those who have mutations that are different (Fedorov, Müller, & Knapp, 2010). Analyses 
targeted to each individual are necessary because cancers affecting the same tissue in 
different patients have a diverse set and number of mutations (Fedorov et al., 2010).  
Today, biopsies of tumors are taken so that cancer can be diagnosed based on 
histology, but it is still too expensive to genetically sequence or run quantitative 
proteomics on every tumor. However, if we determine which kinase genes to target, just 
these specific kinases can be assayed, cutting the time and cost of breast cancer 
diagnoses. Many academic research laboratories study protein kinases, but Fedorov et al. 
found that most published research was conducted on 1-5% of all kinases with 
approximately 25% having unknown function and about 50% vastly uncharacterized 
(Fedorov et al., 2010). I assess methods for processing next-generation sequencing data, 
specifically RNA-sequencing data (RNA-seq), to study all human protein kinases and 
look for new driver mutations in a TNBC cell line in Chapter 2. In Chapter 3, I show 
methods to determine which kinase genes are most responsible for changes in protein 
activity upon treatment with kinase inhibitors.  
 Since most academic and commercial research is focused on the same small set of 
protein kinases, there is a lack of resources for researchers who want information on all 
kinases, apart from a few government funded projects that have information for all genes 
or proteins. Many of the existing websites or databases for kinases appear have been 
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abandoned, with broken web domains or websites that have not been updated in years. In 
Chapter 4, I present a new kinome database that has facts for all 518 human protein 
kinases. The database has a focus on breast cancer and has information about cell types, 
kinase inhibitors, and real experimental data.  
 
Previous Methods to Predict Gene Signatures and Networks 
Many studies are designed to find gene signatures specific to diseases such as 
cancer to use in predicting prognosis, response to treatment, and/or death. In 2002, van ‘t 
Veer et al. found a 70 gene prognosis profile by applying a classification method using 
correlation coefficient, rank-ordering of genes, and ‘leave-one-out’ cross validation on 78 
DNA microarrays of sporadic lymph-node-negative breast cancer patients (van  ’t Veer et 
al., 2002). In additional studies, they showed that their gene-expression profile performed 
better as a predictor of disease outcome in young breast cancer patients than standard 
clinical risk factors (Buyse et al., 2006; Chang et al., 2005; van de Vijver et al., 2002). 
Other researchers assessed the method used by van ‘t Veer et al. and other gene 
signature studies because the overlap between the predicted gene sets was nearly zero 
genes (Ein-Dor, Kela, Getz, Givol, & Domany, 2005). Focusing on data from van ‘t Veer 
et al., they found that the set of 70 predictive genes outputted by the method was not 
unique and changed based on the subset of patients used in the analysis (Ein-Dor et al., 
2005). The variation in gene sets is likely because several genes correlate with patient 
survival with little differences in the correlation values (Ein-Dor et al., 2005).  
Additional statistical measures such as risk scores, Pearson correlation, and 
ranking have also been applied to microarray datasets to identify sets of signature genes 
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for specific or even across many different types of cancer (Chen et al., 2007; Liu et al., 
2007; Xu, Geman, & Winslow, 2007). The methods described are far from perfect in 
predicting response in all cancer subtypes. It is still difficult to genetically screen all 
patient tumors due to cost, time, and analysis restraints. 
Kinases have been shown to acquire drug resistance to inhibitors so combination 
therapies may be necessary for sustained effectiveness (Lo, 2012; Ocaña, Amir, Seruga, 
Martin, & Pandiella, 2012). Many clinical trials are assessing combinatorial therapies of 
targeted kinase inhibitors in cancer (Al-Lazikani, Banerji, & Workman, 2012). Knowing 
all possible connections between kinases in the kinome network would help predict 
combination therapies. In Chapter 3 I use computational methods to find kinase networks. 
The use of high-throughput technologies, such as DNA microarrays, next-
generation sequencing (NGS), and high-throughput proteomics has greatly broadened the 
scope of cancer genomic and proteomic research studies. There exist many computational 
methods and statistical models for microarray generated data, however, the development 
of appropriate tools for the analysis of NGS and high-throughput proteomics still remains 
a challenge, partly due to the sheer amount of resulting data. NGS, particularly RNA-seq, 
has a wide variety of applications including differential gene expression, gene discovery, 
mutation/SNP discovery, novel transcripts, and novel isoforms. 
 Here, I present a global look at the kinome of breast cancer, primarily focusing on 
TNBC. My approach is applicable to any type of cancer for which there is next-
generation genomics and proteomics data. Prior information about genes is not required 
to find the kinase genes in RNA-seq data, which is not the case for microarrays that need 
probes for each gene. No previous studies have combined RNA-seq data with 
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Multiplexed Inhibitor Beads coupled with Mass Spectrometry (MIB/MS) data for the 
TNBC kinome and there is no existing TNBC kinome signature or network that is used to 
predict drug combinations. Knowledge of the TNBC kinome transcriptome and proteome 
will lead to new drug targets and rational combination therapies for treatment of TNBC. 
In addition, a kinome database online resource with experimental data will allow 
researchers to further characterize protein kinases and study this cancer subtype to aid in 




	  CHAPTER TWO 
 
BREAST CANCER TRANSCRIPTOME PROFILING USING NEXT-






Transcriptome profiling requires obtaining transcript expression data for all genes 
and was made easier with the development of RNA-seq. Unlike microarrays or 
hybridization- based techniques, RNA-seq does not rely on existing knowledge of the 
genome sequence nor have detection limitations due to background levels an`d signal 
saturation (Wang, Gerstein, & Snyder, 2009). RNA-seq is also getting increasingly less 
expensive with competition between next-generation sequencing companies and the 
development of new sequencing machines that can generate more data in less time. 
Researchers can take advantage of the amount of data produced by multiplexing samples 
using unique primers for each experimental condition.  
The general protocol of RNA-seq is that a population of RNA is converted to a 
cDNA fragment library with adaptors attached to one or both ends. The fragments may 
be amplified then sequenced from one (single-end sequencing) or both ends (paired-end 
sequencing) to produce millions of 30-400 base pair (bp) reads (Wang et al., 2009). The 
number of reads and the read lengths are increasing as the technology improves. RNA-
seq can be performed on any high-throughput sequencing platform (Wang et al., 2009). 
Many bioinformatics groups have developed different computational tools for the 
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alignment and analysis of RNA-seq data. There is currently no standard analysis protocol 
or program that all researchers use to process the data. 
TNBC’s are comprised of the Basal-like and Claudin-low breast cancer subtypes 
and lack estrogen and progesterone receptors, as well as the HER2 targets for treatments. 
Basal-like and Claudin-low breast cancers have distinct biological characteristics. Basal-
like breast cancer highly expresses proliferation genes and the basal cluster, which is a 
unique gene cluster that includes potential drug targets EGFR and c-kit. Claudin-low 
breast cancers have low expression of proliferation genes, have lost cell-cell adhesion 
molecules, and show expression of epithelial-mesenchymal transition (EMT) and stem 
cell feature-associated genes. TNBC has been found to be more prevalent in younger 
(premenopausal) women and in young African American women (Carey et al., 2006; 
Herschkowitz et al., 2007). TNBC is typically more aggressive than other breast cancer 
subtypes and is more difficult to treat, leading to a poorer prognosis for patients (Dent et 
al., 2007).  
Here, we characterized the kinase transcriptome in breast cancer samples, with a 
focus on TNBC, using RNA-seq data. For the analyses, we investigated some of the most 
widely used alignment programs at the time: Bowtie and Burrows-Wheeler Alignment 
tool (BWA) (Langmead, Trapnell, Pop, & Salzberg, 2009; Li & Durbin, 2009). We 
compiled a list of all kinases and developed a computational analysis protocol for 
obtaining kinase transcripts from raw RNA-seq outputs. The analysis begins with a 
stringent kinase transcript-finding protocol to optimize reads included from a short-read 
(35-bp) protocol. This method was followed with a study focused on longer read (76-bp) 
TNBC RNA-seq samples including an investigation to find novel driver mutations in a 
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TNBC cell line. Evaluation of the kinase transcripts found shows that a majority of the 
kinome is expressed in each cell type at varying levels. Knowledge of these transcript 
expression levels is an additional tool for investigations into the kinome of TNBC and 
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METHODS 
Data Sources 
The Johnson Lab prepared cDNA libraries for next-generation RNA-sequencing 
in three breast cancer cell lines: MDA-MB-231, BT474, and MCF-7, and a non-
cancerous control cell line: HuMEC (TERT-immortalized mammary epithelia). Two 
lanes of sequencing per cell line were completed using the Illumina sequencing platform 
producing 35-bp single-end reads.  
76-bp Illumina RNA-seq data from The Cancer Genome Atlas (TCGA) was 
obtained to profile patient’s Claudin-low breast tumor and two Claudin-low TNBC lines, 
SUM159 and MDA-MB-231.  
RNA-seq Alignment and Kinase Analysis 
A reference dataset of human mRNA transcripts was downloaded from NCBI 
build 37 (hg19) and reformatted it to be FASTA format to use in the alignment. The 
analysis software Bowtie was used in the alignment of the first set of shorter RNA-seq 
reads. Default parameters were not used in the alignment. Instead, due to our desire to 
provide a high-quality characterization of the kinase repertoire in each cell line, we 
performed an interactive procedure of alignments with multiple levels of stringency. The 
procedure is detailed below (see Results). Upon alignment, in-house scripts were used to 
quantify read counts for kinases. Kinase genes with greater than 50 reads per lane were 
summed for each cell line. 
The longer 76-bp read data was aligned to the UCSC human knownGene mRNA 
from NCBI build 37 (hg19) using Bowtie (Langmead et al., 2009). The alignment was 
performed allowing just one mismatch in each read and only the best resulting alignment 
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was reported for each aligned read. Duplicate reads were removed using Picard 
(http://picard.sourceforge.net) and in-house scripts were used to calculate read counts for 
all genes and protein kinase genes were parsed from the list. The read counts were 
summed for all isoforms of each kinase gene and again we required that the kinase genes 
have greater than 50 reads each. 
RNA-seq Normalization 
The quantified kinase transcript counts were normalized with a calculation of 
reads per kilobase of exon model per million mapped reads (RPKM) (Mortazavi et al., 
2008). RPKM is calculated with the formula:  
𝑅𝑃𝐾𝑀 = 10!×𝐶𝑁×𝐿  
where C is the number of reads that mapped to exons, N is the total number of mappable 
reads, and L is the sum of exons in base pairs. Median isoform lengths were used in the 
RPKM calculations to be consistent with TCGA analysis methods. 
The raw kinase transcript read counts for the 76-bp data were also RPKM 
normalized as described for the data above (Mortazavi et al., 2008). The value of “N” 
(total number of mappable reads) in the RPKM formula was defined as the total number 
of aligned reads minus the duplicate reads. The mean isoform length for each gene was 
used in the RPKM calculations. 
Mutation Discovery in RNA-seq Data 
 The possible presence of driver mutations and SNVs in SUM159 was explored by 
using the raw 76-bp SUM159 RNA-seq reads from the TCGA. The reads were re-aligned 
to the UCSC knownGene mRNA transcripts, but using the computational alignment 
program, BWA (Li & Durbin, 2009). Samtools was then used to generate a pileup of 
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possible mutations in the data where sequences aligned, but with mismatches (Li et al., 
2009). Potential mutations that occurred in kinase transcripts were parsed from the pileup 
file and filtered using in-house scripts. To check for any nonsynonymous mutations, the 
original UCSC knownGene mRNA was translated in the six potential protein-coding 
frames and checked for the longest resulting protein starting with the start codon, ATG, 
to find the protein-coding region. The position of each mutation was checked to see if it 
was found within the coding region and if the mutation caused an amino acid change. 
Upon compiling lists of missense and nonsense mutations, the amino acid changes were 
compared to known natural variants listed on Uniprot.  
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RESULTS AND DISCUSSION 
Transcriptome Profiling of Protein Kinases in Breast Cancer Cell Lines 
To characterize protein kinases, we obtained raw Illumina RNA-seq data from the 
Johnson Lab for four cell lines: MDA-MB-231 (Claudin-low), BT474 (HER2/Neu), 
MCF-7 (luminal B) and HuMEC (TERT-immortalized mammary epithelia). RPKM 
normalization was used to characterize the expression of kinases for each cell line at the 
level of mRNA transcripts (Midland et al., 2012). The reads were aligned to human 
mRNA transcripts from hg19 using Bowtie and the alignment procedure is detailed as 
follows (Figure 2.1): 
1) Perform alignments of reads allowing for zero mismatches between the read 
and the reference sequence. 
2) Reads that aligned perfectly AND to only a single kinase gene are assigned to 
the “unique alignment” category. 
3) Reads that align perfectly, but to multiple reference sequences, are processed to 
distinguish between a read that aligned to multiple kinases or multiple isoforms 
of a single kinase gene vs. a read that aligns without error to multiple different 
genes (including non-kinases). 
4) Align with 28 base seed with 2 mismatches allowed (typical default setting) 
a) This step serves to filter out reads that cannot be aligned even under 
these non-stringent conditions, as they are not included in the further 
analyses (Figure 2.1, red boxes). 
5) Allow 1 mismatch on the end of the read. 
6) Allow 1 mismatch in the entire read. 
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7) Allow 2 mismatches on the end of the read. 
8) Allow 2 mismatches in the entire read. 
First, reads aligning uniquely to one transcript were outputted (Figure 2.1, green 
boxes). The list of reads hitting multiple transcripts were then realigned to the reference 
mRNA transcripts (Figure 2.1, yellow boxes). Reads consisting of all “A” or “T” 
nucleotides were removed before aligning. The majority of reads aligned to the reference 
mRNA transcripts with most reads hitting multiple transcripts. In-house scripts were used 
to quantify read counts for kinases. Reads that aligned to one kinase uniquely were 
assigned a count of one. The reads aligning to multiple transcripts could hit: 1) different 
isoforms of the same kinase, 2) several different kinase genes, 3) a kinase gene and other 
genes, 4) or only other non-kinase genes (Figure 2.1, blue and orange boxes; shown only 
once as an example, but done for reads in all multiple alignments (Figure 2.1, yellow 
boxes)). The read counts that hit different isoforms of the same kinase were summed for 
each gene and reads hitting different kinases were given a fraction of a count based on the 
number of genes that were hit (Appendix 1). Reads aligning to kinases and other genes 
were not included in the analysis. The inclusion of fractional counts did not alter the 
overall count data or relative numbers between genes. Kinase genes with at least 50 reads 
per lane were summed for each cell line. Then the quantified kinase transcripts were 
RPKM normalized using median isoform lengths (Appendix 2).  
Somewhat surprisingly, each cell line was found to express approximately 365-
385 kinases of the 518 kinases in the human kinome, with little variation in the relative 
numbers of kinases in the four lines (Table 2.1, Figure 2.2). Only 5-15 kinases are 
expressed uniquely in a given cell line when using a stringent criterion of greater than 50 
	   15	  
reads per gene. In BT474 cells, Her2/Neu is highly overexpressed, while in MDA-MB-
231 cells AXL (UFO) is the highest expressed kinase transcript. We are aware of the 
possibility that specific mRNAs and proteins may have a low level of expression with 
<50 reads per gene. Many kinases are expressed at lower read levels, which suggest their 
protein expression is also low. Therefore, the number of kinases captured by MIB/MS at 
the protein level is likely greater than the 40-50% we have found using the >50 read 
RNA-seq analysis.  
Analysis of Kinase Transcripts in TNBC 
The TCGA provided us with longer read (76-bp) Illumina RNA-seq data for 
MDA-MB-231, SUM159, and a patient Claudin-low tumor. Multiple alignment programs 
were assessed before we decided to align reads to the UCSC human knownGene mRNA 
from NCBI build 37 (hg19) using Bowtie, allowing just one mismatch per read 
(Langmead et al., 2009). Reads were summed for kinase transcripts (Appendix 3). As in 
our previous study, we calculated RPKMs to normalize kinase read counts for which 
there were greater than 50 reads per gene (Appendix 4) (Mortazavi et al., 2008). We 
found better RNA-seq transcriptome coverage of the kinases in this study, finding 400-
500 distinct kinases per cell type (Table 2.2, Figure 2.3A and B). The increase in reads is 
likely due in part to the longer 76-bp reads compared to the 35-bp and because we started 
out with more lanes of raw data: 3-4 lanes per sample, compared to 2 lanes for the 
previous cell lines. The patient tumor was found to have the most kinases and had 43 
unique kinases, which was much more than we previously found when comparing cell 
lines. The greater number of unique kinases makes sense because tumors are made up of 
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many different kinds of cells, not just breast cancer cells, so we expect to find more genes 
expressed in the sample.  
We compared RPKM-normalized RNA-seq data for BT-474, MCF-7, MDA-MB-
231, and SUM159 cell lines to HuMEC and plotted the kinase fold change relative to 
HuMECs in alphabetical order (Figure 2.4). The kinase points were scaled relative to the 
number of raw read counts, so a point with a large diameter indicates larger numbers of 
raw reads. If a cancer cell line kinase RPKM value is greater than the corresponding 
HuMEC kinase RPKM value, then the fold change will be greater than one. If the cancer 
cell line kinase RPKM value is less than the HuMEC kinase, the fold change is less than 
one. 
Mutation-Finding in SUM159 
Since SUM159 was found to not have any highly overexpressed kinases, we 
looked for possible driver mutations and SNVs by reanalyzing the RNA-seq reads. The 
alignment program BWA was used to align reads to the UCSC knownGene mRNA 
followed by analyses with Samtools to generate a pileup file of mutations (Li et al., 2009; 
Li & Durbin, 2009). The mutations that occurred in kinases were parsed from the pileup 
file and filtered to only include confident hits. We then wanted to check for any 
nonsynonymous mutations that may alter protein function. We translated the original 
UCSC knownGene mRNA and found the coding region of the mRNA. Since the position 
of each mutation was known, we checked if the mutation fell within the coding region 
and if the mutation caused a change in the amino acid that was encoded, which could 
result in a nonsense (stop codon) or missense change (different amino acid). We found 31 
potential missense mutations and one potential nonsense mutation (Table 2.3). Upon 
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checking the possible mutations in all isoforms of each kinase, we found that nearly all of 
our missense mutations resulted in known natural variant amino acid changes. Therefore, 
our analysis did not result in finding any likely driver mutations in SUM159 protein 
kinases. A study of somatic mutations of protein kinase genes in 10 different types of 
cancer found that breast cancer had a lower prevalence of mutations than cancers that 
have a higher turnover or epithelia that is repeatedly exposed to mutagens, such as lung 
or colorectal (Greenman et al., 2007). These results suggest that the underlying 
mechanism which fuels the behavior of this breast cancer line must derive from more 
complex mechanisms than simple driver mutations in kinases and we must therefore 
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CONCLUSIONS 
We have characterized the kinome of several breast cancer cell lines, made 
comparisons of the breast cancer kinase transcriptomes to one another, to a control, and 
to a patient tumor sample. The broad scope of computational analysis techniques used 
here includes the untargeted kinases and not just the handful of kinase genes that are 
frequently studied by a majority of kinase research laboratories. Here, we developed 
methods to optimize the use of short-read RNA-seq data in order to obtain read counts of 
genes and calculate normalized values for large gene lists. We also discussed and 
explored how RNA-seq data can be used to find potential driver mutations in a TNBC 
cell line.  
In principle, our approach is applicable to any RNA-seq data where the analysis is 
focused on all gene transcripts, kinase genes, or another set of genes. All cells express 
protein kinases and oftentimes in cancer, kinase gene expression is altered or the kinases 
have mutations. Many studies have analyzed breast cancer using microarrays, giving 
some initial insight into the disease. RNA-seq has the potential to increase our 
understanding of how gene expression varies, what mutations are present, and much 
more.  
Analysis of RNA-seq data remains a challenge and the field does not have a 
standard set of methods or experimental design. Computational tools and techniques can 
help mine the data and are being increasingly developed as the cost of high-throughput 
sequencing decreases. As the cost of sequencing decreases, better experimental design is 
possible, allowing for more sample replicates and the application of advanced statistical 
techniques to find differential gene expression. Increased knowledge of the kinase 
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transcriptome and how it varies between tumors and healthy tissue will not only further 
our basic comprehension of cancer, but may also provide clinical targets to treat the 
disease.  
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Figure 2.1. Flowchart of Bowtie Alignment Procedure. Multiple levels of 
stringency were applied to obtain an accurate count of reads for protein kinases. Read 
counts that aligned uniquely (green boxes) were given a count of one and the reads 
hitting multiple transcripts (yellow boxes) were realigned with new parameters.  




Table 2.1. RNA-seq protein kinases per cell line. 
  BT-474 MDA-231 MCF-7 HuMEC 
>50 reads per gene 368 376 384 378 
 






Figure 2.2. Venn Diagram Showing Overlap of Protein Kinase Transcripts 
Between Cell Lines. RNA-seq reads for four cell lines were aligned to human genome 
19 (hg19) mRNA transcripts using Bowtie. The venn diagram displays the overlap of 
protein kinases with greater than 50 aligned reads and shows that most kinases were 
found to be in all cell lines and few kinases were found to be unique to a specific cell 
line. There are 365-385 total kinases expressed in the four cell lines using this read 








Table 2.2. RNA-seq protein kinases per TNBC cell type. 
  SUM159 MDA-231 Patient 
>50 reads per gene 403 402 455 
 






Figure 2.3. Venn Diagram and Kinase Tree Showing RNA-seq Coverage. (A) 
Venn diagram and (B) kinome tree shows kinase expression defined by RNA-seq 
across patient tumor TNBC and MDA-MB-231 and SUM159 cell lines. 78-88% of the 










Figure 2.4. Scatterplot of Cancer Cell Line Kinase RPKM Fold Changes Relative 
to HuMECs. RPKM values were calculated for kinase genes with greater than 50 read 
counts for BT-474, MDA-MB-231, MCF-7, and HuMEC RNA-seq data. Kinases are 
ordered alphabetically along the x-axis and the point sizes were scaled relative to the 
number of raw read counts; large-diameter points indicate larger numbers of raw read 
counts. Fold change relative to HuMEC is indicated on the y-axis. Fold change 
calculations with zero in the denominator (no HuMEC expression) are not shown.  
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ALPK2	   6683	   A	   ATA	   I	   G	   GTA	   V	   Missense	  
ATR	   754	   T	   ATG	   M	   C	   ACG	   T	   Missense	  
ATR	   1114	   A	   GAC	   D	   G	   GGC	   G	   Missense	  
CDK10	   580	   C	   CGG	   R	   T	   TGG	   W	   Missense	  
CDK10	   640	   G	   GAG	   E	   A	   AAG	   K	   Missense	  
CDK11A	   1688	   T	   GTG	   V	   G	   GGG	   G	   Missense	  
CHUK	   857	   G	   GTA	   V	   A	   ATA	   I	   Missense	  
EIF2AK3	   2312	   G	   GCT	   A	   T	   TCT	   S	   Missense	  
IRAK1	   1674	   C	   TCG	   S	   T	   TTG	   L	   Missense	  
IRAK2	   716	   C	   CGC	   R	   G	   GGC	   G	   Missense	  
IRAK2	   1250	   C	   CTG	   L	   G	   GTG	   V	   Missense	  
IRAK2	   1369	   T	   GAT	   D	   A	   GAA	   E	   Missense	  
MAP3K1	   2917	   G	   GAT	   D	   A	   AAT	   N	   Missense	  
MAP3K1	   3217	   G	   GTC	   V	   A	   ATC	   I	   Missense	  
MAPK6	   1662	   C	   CTG	   L	   G	   GTG	   V	   Missense	  
MAST3	   587	   C	   ACG	   T	   T	   ATG	   M	   Missense	  
MAST3	   2581	   G	   GGC	   G	   A	   AGC	   S	   Missense	  
MKNK2	   533	   A	   ACC	   T	   G	   GCC	   A	   Missense	  
PINK1	   1112	   G	   GCC	   A	   A	   ACC	   T	   Missense	  
PRKACB	   1816	   G	   GGA	   G	   C	   CGA	   R	   Missense	  
PRKACB	   1816	   G	   GGA	   G	   T	   TGA	   *	   Nonsense	  
PXK	   1490	   A	   AAG	   K	   G	   AGG	   R	   Missense	  
RIPK4	   2044	   A	   ATG	   M	   G	   GTG	   V	   Missense	  
ROCK2	   1741	   C	   ACT	   T	   A	   AAT	   N	   Missense	  
SGK223	   292	   G	   GTG	   V	   A	   ATG	   M	   Missense	  
SIK1	   170	   G	   GGT	   G	   A	   AGT	   S	   Missense	  
SIK1	   1971	   C	   GCC	   A	   T	   GTC	   V	   Missense	  
SPEG	   6566	   C	   CCT	   P	   T	   CTT	   L	   Missense	  
SPEG	   9236	   A	   CAC	   H	   G	   CGC	   R	   Missense	  
STK17A	   1235	   A	   AAG	   K	   G	   GAG	   E	   Missense	  
TRPM7	   4709	   C	   ACT	   T	   T	   ATT	   I	   Missense	  




	  CHAPTER THREE 
 
COMPUTATIONAL APPROACHES TO IDENTIFY BREAST CANCER 
SUBTYPE SPECIFIC KINOME SIGNATURES USING MIB/MS KINOME 






In parallel with the RNA-seq analyses, our collaborators in Gary Johnson’s lab 
helped advance a chemical proteomics technique that couples Multiplexed Inhibitor 
Beads (MIBs) with mass spectrometry (MIB/MS) to characterize the activity of 
endogenous kinases in cell samples. The approach was shown to quantitate the kinase 
activity and drug responsiveness of 50-60% of the expressed kinome (Duncan et al., 
2012). The MIBs are made up of mixtures of specific and pan-kinase inhibitors. While 
various laboratories developed aspects of the initial methodology (Bantscheff et al., 2007; 
Oppermann et al., 2009), the Johnson Lab extended MIB technology with the use of 
multiple inhibitors coupled to beads layered in a column to enrich for lower abundance 
kinases. They had observed that more highly abundant kinases and ERK1/2 were 
suppressing binding of the less abundant kinases. In studies involving cell lines, Stable 
Isotope Labeling by Amino acids in Cell culture (SILAC) is used to isotopically label 
proteins for quantitative proteomics. Used along with MIBs and mass spectrometry, the 
kinase expression and post-translational modification of up to three cell populations can 
be directly compared. 
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A 60 protein proteome signature of differentially expressed proteins was found 
for invasive ductal breast carcinoma in three patients using unsupervised principle 
components analysis (PCA) applied to liquid chromatography mass spectrometry peptide 
fragmentation data (Röwer et al., 2009). The study was a proof of concept to identify 
tumor from control samples. The analysis was later further refined using samples from 
six patients with 2D gel analysis and mass spectrometry followed by PCA and 
hierarchical clustering analyses (Röwer et al., 2011). The follow-up study found a sub-
signature of 20 proteins that still showed effective separation power when identifying 
differential protein expression (Röwer et al., 2011). The breast cancer subtypes of the 
tumors included in the studies are unclear and the methods used to identify the protein 
signatures are far from use in the clinic without further validation.  
As we have learned more about biology and with the advent of high-throughput 
technologies, researchers have been moving away from the “molecular biology 
paradigm” (Bensimon, Heck, & Aebersold, 2012). The paradigm assumes there is a direct 
link between gene and protein function with proteins arranged in linear pathways without 
any feedback to the upstream proteins (Bensimon et al., 2012). Advancements in 
genomics and proteomics enable scientists to reconstruct biological networks that are 
more accurate in describing cellular function. Network reconstruction is complicated 
because molecular networks are dynamic and not uniform between individuals due to 
genetic background, epigenetic changes, differential expression, network reprogramming, 
and exogenous signals (Pe’er & Hacohen, 2011). Understanding these differences can 
help explain why a targeted therapy can cause different effects in patients with the same 
mutation and tumor type. Cells must be perturbed in order to assess network activity, 
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response, and potential because basal levels of signals could be indistinguishable between 
cancerous and healthy cells (Pe’er & Hacohen, 2011). Obtaining tumor samples is 
invasive and difficult, therefore, use of cancer models, such as cell lines, is critical in 
studying cell perturbations to construct networks and determine nodes that are viable 
drug targets before administering therapies to patients.  
Just as gene expression does not always directly correlate with protein expression, 
protein expression does not directly translate to protein activity. Using the MIB/MS 
technique, we have kinase activity data for several breast cancer cell lines and the C3Tag 
genetically engineered mouse model (GEMM), including quantitative data for cells 
treated with mitogen-activated protein kinase kinase (MEK) inhibitors. Here, I apply 
statistical pattern recognition methods and a multivariate method to the Johnson Lab’s 
MIB/MS data to find kinase activity signatures specific to breast cancer subtypes. I also 
conducted a preliminary study of methods for constructing simple networks for TNBC 
model systems using MIB/MS data as another step towards finding novel targeted 
combination therapies to treat TNBC.  
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METHODS 
Data Sources 
Our collaborators in the Johnson Lab used SILAC labeling with MIBs and mass 
spectrometry to quantify binding of protein kinases in the breast cancer cell lines: MDA-
MB-231, BT474, MCF-7, and SUM159, and a non-cancerous control cell line: HuMEC. 
Kinase activity was also profiled in C3Tag mice, a mouse model of TNBC. Quantitative 
proteomics time course experiments were conducted for the four cell lines mentioned 
above (BT-474, MDA-MB-231, MCF-7, and HuMEC) in response to the EGFR/HER2 
inhibitor, lapatinib. MIB/MS was performed on TNBC cells treated with MEK inhibitors 
(AZD6244 and U0126) at various time points. SUM159 was also treated with BEZ235, 
which targets the kinase MTOR.  
Statistical Pattern Finding Techniques 
Principle components analysis was performed with Matlab (Version 7.13.0, 
R2011b, The Mathworks, Inc., Natick, MA, USA). PCA is applied to data matrices to 
extract dominant patterns with goals such as simplification, data reduction, outlier 
detection, variable selection, and prediction (Wold, Esbensen, & Geladi, 1987). Our data 
matrix here consisted of rows of kinases as “objects” and “variable” columns of different 
times of treatment. PCA transforms the data to turn a set of observations of variables that 
may correlate into principal components, a set of linearly uncorrelated variables. The first 
principal component has the largest variance and subsequent components have the 
highest variance, but must be orthogonal to the previous components.  
K-means clustering and principle components analysis was conducted with R 
(Version 2.14.1, The R Foundation for Statistical Computing, Vienna, Austria). K-means 
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is a non-hierarchical cluster analysis method. The goal is to partition observations, in this 
case kinases, into k clusters where each observation falls into the cluster with the nearest 
mean value. The k-means clusters were plotted on the first two PCA principal 
components axes (Peeples, 2011). 
Clustergram objects were also created and displayed as heat maps with 
dendrograms using Matlab. The clustergram function computes hierarchical clustering 
with Euclidian distance metric on a data matrix. The method is often applied to gene 
expression data with rows being genes and columns are samples. In our case the data 
matrix consisted of kinase activity as rows and clustering was computed either across 
time for the same sample or across different drug treatments and cell types.  
Co-inertia analysis (CIA) was also performed with R (see version above). CIA is 
a multivariate method for comparing two different sets of data that measure different 
traits in a system. In general, CIA conducts PCA on both data sets and uses the 
information from the PCA analysis to identify how the data sets co-vary. The method has 
been applied extensively to ecological data and has been applied to link proteomic and 
gene expression data (Dray, Chessel, & Thioulouse, 2003; Fagan, Culhane, & Higgins, 
2007). We explored the applicability of CIA to two sets of MIB/MS data for drug treated 
cells.   
Network Construction  
 Networks were constructed and plotted using Mathematica (Version 8.0, Wolfram 
Research Inc., Champaign, IL, USA). The preliminary network analysis involves 
identifying correlations between kinases and/or conditions, depending on the orientation 
of the data being analyzed. Kinase nodes are connections if their corresponding 
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correlation value exceeds a specified threshold and edge lengths are arbitrary. For the 
analysis here, we used data for one cell type across several drug conditions and identified 
correlations between the kinases across conditions.  
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RESULTS AND DISCUSSION 
MIB/MS Profiling of Protein Kinases  
Using layered MIB columns with mass spectrometry (MIB/MS), we found 160-
180 unique kinases per cell type or approximately 30% of all kinases and about 40% of 
expressed kinases as was found with RNA-seq (Table 3.1). These quantitative values 
show that although RNA-seq may show a gene as being expressed, it does not necessarily 
mean that there will be detectible protein activity for the corresponding gene.  
In the subsequent study focusing on TNBC cells and MEK inhibitor treatments, 
we used MIB/MS to capture kinase activation and found approximately 50% of kinases 
being expressed by RNA-seq (Table 3.2, Figure 3.1C and D). More kinase activity is 
being detected, as the MIB/MS technology is being refined and perfected. 
Signature Finding Methods Applied to MIB/MS 
To identify potential protein kinases that would fall into breast cancer subtype 
specific signatures, principal components analysis (PCA) was applied to time course data 
for the initial four cell lines (BT-474, MDA-MB-231, MCF-7, and HuMEC) treated with 
lapatinib (Figure 3.2). PCA reduced the dimensionality of the data and the plots show the 
variables (in this case, kinases) that are responsible for a large part of the variation in the 
data as outliers. HuMEC had the least number of outliers, as we would expect because it 
is a non-cancerous control cell line. MCF-7 had the most outliers, but MDA-MB-231 had 
outliers that were very far removed from most of the data points. UFO (AXL) is known 
to be overexpressed in MDA-MB-231 and appears as one of our outliers (Figure 3.2D). 
Very few of the outlier kinases overlapped between cell lines and although some of the 
outliers are current drug targets, many are part of the unexplored kinome (Fedorov et al., 
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2010). EGFR is a target that has been under investigation to treat TNBC because it is 
over-expressed in the Basal-like subtype (Dent et al., 2007; Liedtke et al., 2008). EGFR 
is a tyrosine kinase and is found on the cell surface where it binds to particular ligands to 
activate downstream signal transduction pathways to control cell differentiation, growth, 
proliferation, and survival (Oda et al., 2005). A trial of EGFR inhibition in TNBC, where 
a subset of breast cancers were examined by gene expression array before and one week 
after therapy, showed that the EGFR pathway was activated in most Basal-like breast 
cancers. However, cetuximab, an anti-EGFR monoclonal antibody, inactivated the 
pathway in a minority of the cancers (Anders & Carey, 2009). These studies along with 
our results suggest that the mechanism that drives this cancer appears to be more complex 
and incorporates alternate pathways rather than being caused by one deregulated kinase 
and more work must be done to find appropriate targets for treatment. 
 We similarly applied K-means clustering and PCA to time course data for 
SUM159 treated with AZD6244 using a procedure that integrates the two analysis 
methods (Peeples, 2011). The times included were 4, 12, and 24 hours of treatment. We 
tested 10 cluster solutions and found four to be the optimal number of clusters for the 
data from a plot of cluster solutions plotted against the Log of the Sum of Squared Error 
(SSE). PCA was conducted on the original data set and samples were plotted on the first 
two component axes with the four clusters outlined (Figure 3.3). The plot shows little 
overlap between the clusters, meaning they are strong at the level of clustering we 
selected and the first two principal components explain 93.84% of the variability. The 
outlier kinases from the PCA analysis are labeled on the plot and we found that many of 
these kinases overlapped with the kinase signature for a reprogrammed kinome 
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determined by the Johnson Lab’s initial analyses (Duncan et al., 2012). In particular we 
found UFO (AXL), JAK1, KCC2G, and PDGFRβ to cluster together and it was 
previously found that these kinases all exhibited increased MIB binding. We also found 
TESK1 to be in this cluster, but this kinase was not found in the earlier reprogrammed 
kinase signature results. In addition, several other kinases, in the fourth cluster on right 
side of the figure, including MP2K1, appear to be significant in distinguishing differences 
in behavior, but were not previously identified as being part of the published kinase 
signature.  
 We performed hierarchical clustering of the SUM159 treated with AZD6244 time 
course data to observe how the kinase activity changed over time (Figure 3.4). Cells were 
treated for 4, 12, and 24 hours and kinase activity was profiled for each time point. From 
the heatmap generated upon clustering, it is easy to see the reprogramming, or changes in 
kinase activity that occur between 4 hours and 12 or 24 hours, that occurs with MEK 
inhibition, as was a result of the initial study. For example, groups of kinases shift from 
low activity (green) at 4 hours to higher activity (red) over time. The activity of many 
kinases shifts depending on the length of inhibitor exposure. Additionally, in the study, 
SUM159 and MDA-MB-231 were both treated with AZD6244 and U0126 for 24 hours. 
Hierarchical clustering of the data shows that the SUM159 cells treated with each 
inhibitor cluster together and the MDA-MB-231 cells cluster together, suggesting that, in 
a global sense, kinome response to these two different drugs is more similar within cell 
lines than between cell lines (Figure 3.5). Such similarities may not exist when looking at 
specific subsets of kinases, where kinase activity may be more similar across drugs than 
across cell lines. 
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Co-Inertia Analysis of MIB/MS Data 
 As a possible signature-finding method, we tested co-inertia analysis to answer 
the question of if there were kinase activity differences in SUM159 cells compared to 
some sort of control under drug treatments. HuMEC was used as the control because it is 
a non-cancerous cell line even though the samples did not receive the same drug 
treatments. SUM159 was treated with U0126, AZD6244, and BEZ235, each for 24 hours, 
while HuMEC was treated with lapatinib for 4, 24, and 48 hours. Both data sets have the 
same number of conditions, but that is not a requirement of CIA. The only requirement 
for this method is that the number of rows must be the same. To satisfy this, only kinases 
that were found in both cell lines for all of the conditions were included in the 
computation.  
CIA was performed and resulting kinase “distances” were plotted in transformed 
space (Figure 3.6). Looking at the plot, the line between the dots and arrowheads shows 
the divergence of the kinase between the data sets. Therefore, a larger divergence 
represents a larger difference in the activation of that particular kinase while a shorter line 
would represent a smaller divergence and a small difference between the two data sets. 
From these results, it appears that SUM159 cells and HuMEC cells differ the most in 
EGFR, GAK, and LYN kinase activation. However, the differences do not appear to be 
that great considering that the divergence of these kinases are within 3 standard 
deviations of the mean of the “distances” between the cell lines. With more accurate data 
and data that is more comparable, such as the same drug treatments administered to two 
cell lines, the analysis could reveal changes in the kinase activation profiles of each 
kinase.  
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Exploration of Kinase Network Construction 
Correlations of kinase activity were calculated across samples SUM159 cells 
treated with AZD6244 (4 samples), U0126 (2 samples), BEZ235 (1 sample), and 
lapatinib (1 sample). The correlation values were used to construct a network graph 
where kinases are nodes and edge connections are formed between kinases if their 
correlation was greater than a specified threshold value of 0.5, in this case (Figure 3.7). 
This threshold value was chosen because it did not display too much noise in the data and 
allowed for quite a few connected. PDGFRB was found to be one of the few highly 
connected nodes, so imatinib, an inhibitor that targets PDGFR, could be further explored 
as a treatment option.  
 Network analysis was also applied to MIB/MS data from C3Tag mouse samples 
treated with AZD6244. Again, correlation values were used to construct a network graph 
(Figure 3.8). For this example, connections between kinases were included if their 
correlation was greater than a threshold of 0.85. A larger value was chosen because there 
are many more correlations compared to SUM159, so a higher number had to be chosen 
for nodes to be visible in the graph. Even with this higher cutoff value, it is difficult to 
see specific nodes that are highly connected. It appears that the network may have 
underlying subnetworks, which is something we could explore further especially as we 
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CONCLUSIONS 
 We have explored the application of statistical signature-finding methods and 
network analyses to MIB/MS data for various breast cancer cells treated with kinase 
inhibitors. Since we did not have access to many samples, it is difficult to draw concrete 
conclusions from the results. As we add more data, it will open doors for more 
complicated multivariate analyses and further refinement of our signature-finding 
methods. We are hoping to gather more data for the cell lines included in our study from 
the ArrayExpress Archive (http://www.ebi.ac.uk/arrayexpress/), particularly to add to the 
CIA. An interesting future analysis would be comparisons of MIB/MS activity to RNA-
seq expression values using CIA. This study would depend on obtaining RNA-seq data 
for inhibitor-treated cells. Many computational-experimental strategies exist to construct 
network models depending on what data is available. While the effects of cancer drug are 
difficult to predict because crosstalk and feedback are complicated processes, network 
construction will help us learn how the mechanism functions. The networks presented 
here may provide a set of initial hypotheses for further investigation, potential therapeutic 
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Table 3.1. MIB/MS captured protein kinases per cell line. 
  BT-474 MDA-231 MCF-7 HuMEC 
Unique Kinase IDs 165 159 168 161 
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Table 3.2. MIB/MS captured kinases per TNBC cell line or tumor. 
  SUM159 MDA-231 Patient 
Unique Kinase IDs 188 202 205 
 





Figure 3.1. Venn Diagram and Kinase Tree Showing MIB/MS Coverage. (A) 
Venn diagram and (B) kinome tree showing kinases captured and identified by MIB-
based proteomics across patient tumor TNBC and MDA-MB-231 and SUM159 cell 
lines. MIB/MS captures 50-60% of the expressed kinome as observed by RNA-seq 
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Figure 3.2. PCA for 4 Cell Lines (HuMEC, BT-474, MDA-MB-231, and MCF-7) 
after Treatment with Lapatinib. (A)-(D) Separate plots of PCA conducted in each 
time course data set. Times included were 4, 24, and 48 hours. Labeled kinases denote 
outliers from the data. (E) Plots from (A)-(D) overlaid to make comparisons between 
the different cell lines upon treatment with lapatinib.  




PCA showing K-means Clusters 
	  
Figure 3.3. Principle Components Analysis (PCA) and K-means of SUM159 
Treated with AZD6244 Time Course Data. A four cluster solution K-means 
clustering and principal components analysis was conducted on a time course of 
SUM159 treated with AZD6244 for 4, 12, and 24 hours. The outlier kinases that are 
responsible for the most variability in the dataset are labeled. The list of kinases 
outside the plot on the right side all correspond to the dark outlier on the far right of 
the plot. 
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Figure 3.4. Hierarchical Clustering Analysis of SUM159 Time Course Treated 
with AZD6244. This dendrogram and heat map displays how the kinase activity shifts 
from 4 to 12 and 24 hours, showing how kinase activity does not remain suppressed or 
stable with prolonged inhibitor treatment. Green corresponds to low activity and red 
corresponds to high activity. 
  





Figure 3.5. Hierarchical Clustering Analysis of SUM159 and MDA-MB-231 
Treated with AZD6244 and U0126 at 24 Hours. This dendrogram and heatmap 
shows that the kinase activity of SUM159 treated with U0126 is more similar to 
SUM159 treated with AZD6244 than it is MDA-MB-231 treated with U0126. The 
MDA-MB-231 cells with treatment were also clustered together. The different kinase 
activity profiles for each drug are visible and can be compared across the cell lines to 
see that the response is specific to the cell type and inhibitor. 
 
 




Figure 3.6. Results of CIA Analysis Comparing SUM159 to HuMEC. Plot of 
kinase “distances” in transformed space. Each number represents a kinase and 
corresponds to a pair of points. The dot at one end of the line represents the 
normalized row score for the X kinase while the arrowhead at the other end represents 
the normalized row score for the Y kinase. The line between the two points shows the 
divergence of the kinase between the data sets. 
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Figure 3.7. SUM159 Kinase Network. This network diagram shows connections of 
correlated kinases for SUM159 treated with AZD6244, U0126, BEZ235, and lapatinib 
surpassing a correlation threshold of 0.5. Node weight corresponds to average 
activation levels over all conditions for each kinase. PDGFRB is the largest visible 
node.	  
 





Figure 3.8. C3Tag Kinase Network. This network diagram shows connections of 
correlated kinase activity for C3Tag mice treated with AZD6244, surpassing a 




	  CHAPTER FOUR 
 





 As described in Chapter 1, protein kinases are integral to cellular signaling and 
deregulation or overexpression of the genes can lead to many diseases, including cancer.  
There are approximately 518 kinases in the human kinome and many inhibitors are 
administered clinically or are being studied to treat cancers. Given the importance of 
protein kinases to disease, one would think there are many available resources to aid in 
the study of kinases. However, this is not the case and most existing kinase-centered 
websites have turned into non-working links, have not been updated in years, or are not 
easy to use. For example, the Protein Kinase Resource, an academic site with kinase 
sequence and structural information, appears to have last been updated in 2006 (Niedner 
et al., 2006; Smith et al., 1997). Since 1999, kinase.com and kinbase have been 
maintained by Sugen and the Salk Institute to support their publications (Manning, 
Whyte, Martinez, Hunter, & Sudarsanam, 2002). Like the Protein Kinase Resource, 
kinbase also has sequence and protein information, but the kinbase pages are not easy to 
navigate and appear unorganized.  
Existing websites do not display any information specific to cell types, kinase 
inhibitors, or any experimental data that is relevant to kinases. There are a few projects 
that appear to have government funding that do have kinase information, but most have 
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information for all genes or proteins. Since the websites cover the entire genome, they are 
fairly generic and still do not have any experimental data. As the volume of high-
throughput data increases, there is a need for data organization, storage, and accessibility. 
Some publications require data to be made available in a supplement. However, given the 
amount of data that is generated in next generation sequencing experiments, it is often 
impossible for raw data to be available for download and difficult to recreate analysis 
results.  
Here, we present a new kinome database: Kinome DB that has information about 
all 518 human protein kinases. Our database currently has a focus on breast cancer and 
has descriptions for cell types, kinase inhibitors, and real experimental RNA-seq and 
MIB/MS data. The website includes all experimental conditions used and plots of the 
data with the processed data available for download. We hope to collaborate with other 
kinase researchers to make more high-throughput data publically available and that the 
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METHODS 
Data Sources 
 Uniprot names and accession numbers were compiled from the Universal Protein 
Resource (www.uniprot.org). Protein kinase names, Entrez ID’s, and alternative names 
were compiled from the NCBI Gene website. The kinase family tree image on the 
homepage was from Cell Signaling Technology (www.cellsignal.com). Information 
about cell types and inhibitors were found in publications, on breast cancer cell line 
information websites, and on PubChem. Experimental MIB/MS data is from studies 
conducted by the Johnson Lab at UNC. Raw RNA-seq data was also generated by the 
Johnson Lab or from collaborators the TCGA and processed as described in Chapter 1, 
above.  
Website Development 
 Programming was completed in the integrated development environment Eclipse 
(www.eclipse.org) along with the Python plugin, PyDev. All data for Kinome DB is 
stored in a MySQL database. MySQL is an open source relational database management 
system. The open source tool phpMyAdmin was used for the administration of the 
MySQL database. phpMyAdmin can be used to create, modify, and delete databases, 
tables, fields, and rows, so it was useful whenever we needed to drop data tables to reload 
data. A Python script is used populate the MySQL database directly from csv (comma-
separated values) files.  
The open source Python web framework Django (www.djangoproject.com) was 
used for back-end website development. Django uses the model-view-controller design 
and was made for creating data-driven websites. Twitter Bootstrap tools were used for 
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front-end webpage development (http://twitter.github.com/bootstrap/). Matplotlib, a 
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RESULTS AND DISCUSSION 
Data Compilation 
Initially, our collaborators in the Johnson Lab provided us with a list of kinase 
Uniprot abbreviations and accession numbers. Then, corresponding kinase gene names 
and alternate names were found on the NCBI Gene website. Many of the kinase names 
have changed since we first compiled the data, so a lot of manual checking was necessary 
to get an up-to-date and accurate list. The Uniprot accession and the Entrez gene ID 
values seem to be stable. Cell type information was found in online resources and 
inhibitor information was compiled from studies or PubChem (Anastassiadis, Deacon, 
Devarajan, Ma, & Peterson, 2011; Karaman et al., 2008). All RNA-seq and MIB/MS 
proteomics experimental data included in the database has been described in the 
preceding chapters (Chapters 2 and 3).  
Database Population 
Data is loaded into the MySQL database using a Python script from csv files. This 
enables ease of data compilation because researchers usually store data in tables using 
programs such as Microsoft Excel. Each csv column corresponds to a column in the 
MySQL table. MySQL assigns a number as the primary key for tables, so tables can 
easily be connected using other data values as foreign keys and the connected table’s 
primary key will be displayed in the new table.  
Webpage Construction and Design 
 The main component files in Django are models.py, views.py, and urls.py. We 
used a load_data.py script to load data into MySQL tables. The table structures are 
classes defined in models.py where each field in the table is defined as being a slug field, 
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character field, text field, decimal field, foreign key, or other table connection and so on. 
A slug is a short label and only contains letters, numbers, underscores, or hyphens. The 
slug is typically used in uniform resource locators (URLs). Functions to call aspects in 
specific models are contained in views.py and each view function is connected to an html 
template file. Slugs are defined in each view and used by urls.py for each page’s web 
URL.  
 Each view specific html file extends a base template that contains links to style 
sheets, the code for the sidebar with links, and the footer information. That way, this code 
does not need to be on every page. We used front-end components from twitter bootstrap 
(http://twitter.github.com/bootstrap/). Twitter bootstrap is a free collection of tools for 
creating websites and web applications including HTML and CSS-templates for buttons, 
typography, forms, and other web interface parts. We wanted a clean and simple design 
that was easy to navigate.  
Kinome DB Informational Webpages 
 The Kinome DB homepage displays a short description of the website, the Cell 
Signaling kinase family tree, and a sidebar with several links to other pages on our site.  
Each family section of the tree links to the corresponding family information page. The 
sidebar has a link for the homepage at the top, followed by several categories with links: 
Kinases, Families, Cell Types, Inhibitors, Experiments, MIB/MS, RNA-seq, and Data 
(Figure 4.1). There is also a search box that allows users to query aspects on the site, 
which will be explained in more detail below.  
 The Kinases link in the sidebar directs users to a page with a list of all 518 human 
protein kinases (Figure 4.2). The kinases are listed alphabetically split into three columns. 
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Each kinase name links to an individualized kinase page (Figure 4.3). The kinase page 
displays the gene name, which links to the NCBI gene page, the Uniprot name, and 
Uniprot accession number with a link to the corresponding protein Uniprot.org page. 
There is also a list of alternate names, if applicable, and family information with a link to 
the family page on Kinome DB (described below). We saw that some kinases were listed 
as being part of multiple families and if so, we included links to both families. Below the 
information is an iframe displaying the kinase’s GeneCards page. Iframes are inline 
frames used to place another HTML document in a frame on a page. We included the 
GeneCards page because GeneCards has already compiled gene descriptions, functions, 
and additional information that is related, but not directly related to the goal of Kinome 
DB. Kinome DB’s goal is to compile and display kinase information directly relevant to 
experiments.  
 The Families link in the sidebar links to a page with a list of the 10 current kinase 
families or groups: AGC, Atypical, CAMK, CK1, CMGC, Other, RCG, STE, TK, and 
TKL (Figure 4.4). Each name is linked to the specific kinase family page (Figure 4.5). 
The family page has a short description of the family and an alphabetical list of the 
kinases included in that family. A kinase could show up in multiple family lists if we 
found a resource saying it belongs to more than one.  
 The Cell Types sidebar link displays a page with a list of cell types for which we 
have experimental data (Figure 4.6). Currently, this list includes the breast cancer cell 
lines: BT-474, MCF-7, MDA-MB-231, and SUM159, and the patient tumor referred to as 
Patient018. Each cell type has a page that includes general information such as the cell 
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name, organ, tissue, and classification (Figure 4.7). We will expand this list as we obtain 
more experimental data and as we add data for additional types of experiments.  
 The Inhibitors link directs to a page listing several kinase inhibitors that our 
Johnson Lab collaborators have used in various experiments (Figure 4.8). The list 
includes inhibitors: AZD6244, BEZ235, GSK1120212, Imatinib, Lapatinib, SB590885, 
Sorafenib, and U0126. Most of the kinase inhibitors are not specific for just one or two 
related genes, but hit several different kinases. Clicking an inhibitor’s name takes users to 
an inhibitor data page displaying the compound ID with a link to the compound’s 
PubChem page, any synonyms, the IUPAC name, SMILES, kinase targets, and other 
gene targets (Figure 4.9). Clicking the names of kinases listed as targets takes users to the 
individual kinase pages described above (Figure 4.3).  
Kinome DB Experiment Webpages 
 Clicking on Experiments takes users to a page listing the types of experimental 
data that are currently available for viewing and plotting: MIB/MS and RNA-seq (Figure 
4.10). The names are links for general information pages for the two experiment types. 
The MIB/MS link on the Experiments page or on the sidebar directs to the MIB/MS page 
and the RNA-seq links direct to the RNA-seq page (Figures 4.11 and 4.12). The MIB/MS 
page has a short description about the experiment type at the top with a link to 
Experiment2 below. The RNA-seq page also has a short description and it links to the 
RNA-seq experiments: Experiment1 and Experiment3.  
Clicking on the Experiment1 link takes users to a page displaying the experiment 
type, related publication name if the data was published, the PubMed ID with a link to the 
PubMed entry for the publication, and additional information (Figure 4.13). Below that is 
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a list of individual runs related to the experiment and a link to the raw data page. Each 
experiment is split up into runs in cases where another lab member conducted parts of the 
experiment or the experiment consists of different cell types, inhibitors, doses, or 
treatment times. Additionally, each run can have different information regarding the 
analysis component. For example, Experiment1 has 3 runs (Exp1Run1, Exp1Run2, and 
Exp1Run3) that correspond to three cell types: BT-474, MCF-7, and MDA-MB-231. If a 
user clicks on Exp1Run1, they are taken to an information page for the RNA-seq run 
(Figure 4.14). This page displays laboratory experiment and sequencing information. The 
experimental information includes the laboratory name, cell type linking to the cell type 
page, inhibitor, dose, and time (all if applicable), and additional information. Sequencing 
information lists the analysis lab, cycles, sequencing type, counts of total reads, mapped 
reads, duplicate reads, the alignment program used, and additional information. Run 
pages for MIB/MS experiments list similar information, but not including the parts 
specific to RNA-seq analysis.  
Data pages for experiments currently show a list of raw data and a bar plot 
generated with matplotlib of the values. An example data page is shown for an 
abbreviated list consisting of 10 kinase read counts (Figure 4.15). Users can copy the raw 
data table and paste it into Excel, so it can be used for other analyses. We are working on 
adding direct download links for raw data csv or text files.  
 The last component of the sidebar is a search box. The search box performs a 
simple query to allow users to search by kinase gene name, Uniprot name, Uniprot 
accession, or alternate names. They can also search for a family name, cell type, organ, 
tissue, or classification, as well as inhibitor name, inhibitor synonym, or target. 
	   58	  
Experiments are also queried if the search field contains a lab name, cell type, inhibitor, 
and experiment type. Search results are categorized based on Kinases, Families, Cell 
Types, Inhibitors, MIB/MS Experiment Runs, and RNA-seq Experiment Runs. An 
example search for “map2k1” results in the MAP2K1 kinase as well as a list of the 
inhibitors that target MAP2K1 (Figure 4.16). Enabling users to search by the various 
kinase names greatly increases the functionality of our website. Some existing kinase 
websites will only return results if a particular gene name is queried. This can be very 
frustrating or confusing to users so we ensured that all names were searchable.  
  
	   59	  
CONCLUSIONS 
We have developed Kinome DB, a protein kinase website that organizes and 
displays information relevant to kinase-related experiments. Kinome DB displays general 
information about all kinases, kinase families, kinase inhibitors, and cancer cells. We 
compiled many types of data and developed ways of displaying the data in hopes of 
making large-scale kinase research more feasible. More experimental data and 
functionality will be added, especially with regards to plotting and data analysis on site. 
In the future, we will enable users to select a group of kinases across many experiments 
to get specific results or data of interest. We also plan on adding more types of 
experimental data and data related to different types of cancer.  
It is difficult to project the number of people who would use a resource like the 
one we have created. Many experiments are focused on a select few kinases, but as was 
shown in previous chapters, there is a need to approach the kinome in a network-minded 
manner. Inhibitors do not only affect one kinase or kinase pathway and there are bigger 
shifts in the network to circumvent treatments. The database presented here may expand 
the scope of kinase studies and help us understand their role in cancer.  
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Figure 4.1. Kinome Database Homepage. Screenshot of the website homepage 
displaying a clickable protein kinase tree. Each region of the tree links to the 
corresponding kinase family page. The sidebar on the left is displayed on every page 
and has direct links to the kinase, family, cell type, inhibitor, experiments, and data 
pages. There is also a search box to search to search the site.  
 





Figure 4.2. Kinome Database Kinase List Page. Screenshot of the kinase database 
kinase list page. A list of the 518 protein kinases for which we have information about 









Figure 4.3. Kinome Database Kinase Page. Screenshot example of the kinase 
database individual kinase page for AAK1. The page displays the gene name with a 
link to the NCBI gene page for AAK1, the Uniprot name, Uniprot accession number 
with a link to the Uniprot.org page for AAK1, a list of alternate names, and the family 
information with a link to the family page. Below the information is an embedded 
window with the genecards.org page for AAK1, which includes more information 
about the gene’s function, gene and protein information, publications, and more. 
 
 





Figure 4.4. Kinome Database Family List Page. Screenshot of the kinase database 
kinase families page. The page displays the list of the 10 current kinase families or 









Figure 4.5. Kinome Database Family Page. Screenshot example of the kinase 
database individual kinase family page for AGC. The page displays a short description 
of the family with a list of kinases that are included in the family below, which link to 
their individual description pages. 
 





Figure 4.6. Kinome Database Cell Type List Page. Screenshot of the kinase 
database cell types page. The page displays a list of cell types for which we have 
information or experimental data and links to individual pages, which have 








Figure 4.7. Kinome Database Cell Type Page. Screenshot example of the kinase 
database individual cell type for BT-474. The page displays the cell name, organ, 








Figure 4.8. Kinome Database Inhibitor List Page. Screenshot of the kinase database 
inhibitor page. The page displays a list of kinase inhibitors with links to their 








Figure 4.9. Kinome Database Inhibitor Page. Screenshot example of the kinase 
database individual inhibitor page for AZD6244. The page displays the compound ID 
with a link to PubChem, synonyms for the drug, the IUPAC name, SMILES, kinase 
targets, and other targets, if applicable. The kinase targets link to the individual kinase 
pages. 
 




Figure 4.10. Kinome Database Experiments List Page. Screenshot of the kinase 
database experiments page. The page displays a list of the experiment types for which 








Figure 4.11. Kinome Database MIB/MS Experiments Page. Screenshot of the 
kinase database MIB/MS page. The page displays a description and the available 









Figure 4.12. Kinome Database RNA-seq Experiments Page. Screenshot of the 
kinase database RNA-seq page. The page displays a description and the available 
experiments with links to the individual experiment pages. 
 
 




Figure 4.13. Kinome Database Sample Experiment Page. Screenshot example of 
kinase database experiment page for Experiment1. The page displays the experiment 
type, publication name (if applicable), PubMed ID with link to publication page, 








Figure 4.14. Kinome Database Sample Experiment Run Page. Screenshot example 
of kinase database experiment run page for Experiment1, Run1. The page displays 
laboratory experiment information and sequencing information. Experimental 
information includes the laboratory name, cell type with link to cell type page, 
inhibitor, dose, and time (all if applicable), and additional information. The 
sequencing information states the analysis lab, cycles, sequencing type, counts of total 
reads, mapped reads, duplicate reads, the alignment program, and additional 
information. 
 





Figure 4.15. Kinome Database Data Page. Screenshot example of the kinase 
database data page displaying RNA-seq read count data. The page displays a table of 
RNA-seq read counts above and a bar graph of the data below.  
 
 




Figure 4.16. Kinome Database Search Page. Screenshot example of the kinase 
database search page for “map2k1”. The page displays a link for the kinase MAP2K1 
and links for the three kinase inhibitors that inhibit MAP2K1. The search page 
organizes search results into Kinases, Families, Cell Types, Inhibitors, MIB/MS 
Experiment Runs, and RNA-seq Experiment Runs categories.  
 
 






SUMMARY OF FINDINGS 
 Methods to analyze RNA-seq data and characterize the kinome transcriptome 
were presented. Additionally, statistical pattern recognition methods were applied to find 
signatures in MIB/MS data and correlation calculations were used to construct kinase 
networks. We also presented Kinome DB, a website for organizing information about all 
518 protein kinases, kinase inhibitors, breast cancer cell types, and experimental data for 
kinases. For each cell type, we found approximately 70 to nearly 90% of expressed 
kinases using RNA-seq and up to 50% of those kinases were found to have detectable 
activity as defined by MIB/MS. Our signature-finding investigation resulted in 
discovering some outlying kinases that could be part of breast cancer subtype specific 
signatures and the network construction found highly connected kinases that could be 
potential drug targets. We hope that our kinome database will be a widely used resource 
for all kinase researchers. 
 
CHALLENGES 
 Lack of many experimental replicates for all studies prevents us from making 
concrete statements about our findings. Most statistical analyses, especially for 
differential gene expression studies, require at least three biological replicates. Having 
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data for cells treated with many inhibitors and samples for different cells treated with the 
same inhibitor will enable the use of more advanced statistical analysis techniques. 
Experimental validation of our outliers is also necessary. RNAi experiments could be 
used to knock out important kinase outliers or highly connected kinases found in 
networks and inhibitors can administered to cells or mice. There is also a need for 
methods to integrate high throughput data types and high throughput data with other 
experimental data. As basic research progresses, genes that are considered putative 
kinases may be renamed or reclassified. We will have to take issues like this into account 
when keeping our database up to date.  
 
FUTURE DIRECTIONS 
 As high-throughput methods improve with longer RNA-seq reads and better MIB 
design, more experiments can be performed for a lower cost and additional kinases will 
likely be found in the data. Alignment programs that are more accurate for processing 
longer reads have been published, such as Bowtie 2 (Langmead & Salzberg, 2012). 
Ongoing work involves RNA-seq and MIB/MS time course experiments with more cell 
lines treated with additional inhibitors. This new and improved dataset will allow for 
better, more accurate predictions to be made regarding kinase signatures and connections 
between kinases to construct accurate networks.  
Further development on Kinome DB, the kinome database website, will include 
more complicated and customizable computational analyses to take place on the site, 
along with advancements in the displayed graphs or plots of processed data. We hope to 
add more experimental data to the website as it is generated, including data for additional 
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cancer cell types and kinase inhibitors. Additionally, it would be ideal if other kinase 
researchers upload their published experimental data to our site because it would be in a 
more accessible place and in a more usable format than in a publication’s supplement.  
 
CONCLUDING REMARKS 
Characterization of the breast cancer kinome is far from complete. The work 
presented here has led to profiling of the kinase transcriptome in various breast cancer 
subtypes using RNA-seq and MIB-MS. The kinase outlier predictions can be compared 
to newly analyzed data or be tested experimentally in the future. These methods can be 
applied to any cancer for which there is adequate RNA-seq or MIB/MS data with time 
courses and inhibitor treatments. Understanding the mechanisms by which cancers 
manipulate the kinome to promote tumor growth and development will lead to novel drug 
targets and new drug combinations. Novel clinical detection measures and treatments are 
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APPENDIX 1: RNA-seq read counts for expressed kinases 
 
gene	   BT-­‐474	   MCF-­‐7	   MDA	   HuMEC	  
AAK1	   924	   984.5	   2574	   2843	  
AAPK1	   1837	   1668	   2887	   1385.5	  
AAPK2	   184	   0	   657	   0	  
ABL1	   7194.5	   3441	   4612	   2142	  
ABL2	   649	   1086	   26546	   2538	  
ACK1	   745	   1866	   1105	   1020	  
ACV1B	   1561	   2031	   867	   1131	  
ACVR1	   594	   890	   983	   839	  
ADCK1	   445	   490	   0	   124	  
ADCK2	   959	   2202	   541	   969	  
ADCK3	   590	   954	   1306	   720	  
ADCK4	   322	   498	   69	   515	  
ADCK5	   303	   279	   202	   327	  
AKT1	   12180	   16924.5	   4097.5	   4389	  
AKT2	   4678	   4764.5	   3456.5	   3377	  
AKT3	   0	   0	   1597	   472	  
ALPK1	   271	   280	   147	   881	  
ALPK2	   0	   0	   151	   0	  
ALPK3	   277	   203	   0	   66	  
ARAF	   2724	   2361	   1869	   1708	  
ARBK1	   4633	   4707	   2494	   2993	  
ARBK2	   214	   160	   498	   618	  
ATM	   760	   559.5	   1784	   760	  
ATR	   1207	   1805	   1294	   1061	  
AURKB	   655	   1332	   2080	   730	  
AVR2A	   452	   465	   412	   391	  
AVR2B	   206	   928	   900	   324	  
BCKD	   1643	   2517	   1870	   1994	  
BCR	   2031.5	   2176	   670	   2377	  
BMP2K	   391	   329	   1757	   547	  
BMPR2	   1942	   2266	   1497	   2827.5	  
BMR1A	   446	   406	   466	   283	  
BMR1B	   0	   221	   389	   151	  
BRAF1	   430	   314	   611	   316	  
BRD2	   7900	   9008	   15090	   4726	  
BRD3	   2821	   2633	   1456	   872	  
BRD4	   5702	   2683	   8941	   2663	  
BRSK1	   0	   0	   483	   0	  
	   80	  
BRSK2	   0	   95	   0	   0	  
BUB1	   1127	   1923	   4920	   1595	  
BUB1B	   1066	   1092.5	   2016.5	   1097.5	  
CCRK	   188	   420	   0	   118	  
CD11A	   1016.333333	   986.8333333	   967	   1015.166667	  
CD11B	   1143.333333	   1065.833333	   1066	   1140.166667	  
CD2L5	   2159	   1905.5	   1703	   1377	  
CD2L6	   1249	   1300	   419	   493.5	  
CD2L7	   13210	   2076	   4236	   2261	  
CDC2	   1118	   1321	   2528	   729	  
CDC7	   426	   310	   483	   199	  
CDK10	   819	   1366	   627	   767	  
CDK2	   1654	   1878	   2006	   856	  
CDK3	   138	   70	   0	   0	  
CDK4	   5006	   8009	   6670	   1677	  
CDK5	   772	   911	   214	   506	  
CDK6	   439	   1149	   5366.5	   4271	  
CDK7	   489	   991	   1984	   1478	  
CDK8	   380	   663	   571	   613	  
CDK9	   1523	   1960	   2481	   1294	  
CDKL1	   0	   0	   341	   0	  
CDKL2	   0	   0	   0	   62	  
CDKL5	   301	   191	   120	   180	  
CHK1	   717.5	   518	   1381.5	   579	  
CHK2	   254	   560	   192	   220	  
CHKA	   1357	   848	   1394	   130	  
CLK1	   746	   603	   1180	   456	  
CLK2	   772	   1267	   698	   512	  
CLK3	   1148	   1540	   1557	   930	  
CLK4	   264	   273	   443	   134	  
CSK	   2024	   3902	   1318	   2064	  
CSK21	   2353	   1473	   3989	   1950	  
CSK22	   1157.5	   561	   1522	   1962	  
CSKP	   2519	   1582	   2835	   2028	  
CTRO	   1609	   1661	   2459	   1545	  
DAPK1	   0	   52	   252	   1451	  
DAPK2	   148	   133	   0	   302.5	  
DAPK3	   1094	   1120	   1568	   1097	  
DCK	   488	   517	   772	   331	  
DCLK1	   623	   431	   0	   0	  
DCLK2	   243	   0	   255	   0	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DDR1	   9576	   14672	   897	   16482	  
DDR2	   0	   0	   54	   0	  
DMPK	   1084	   794	   657	   397	  
DUSTY	   655.5	   1392.5	   941	   1170.5	  
DYR1A	   1614	   1767	   2699	   1171	  
DYR1B	   362	   639	   147	   272	  
DYRK2	   901	   1241	   641	   1219	  
DYRK3	   0	   0	   584	   85	  
DYRK4	   272	   0	   288	   357	  
E2AK1	   10283	   9987	   2546	   4003	  
E2AK2	   777	   1205	   892.5	   917	  
E2AK3	   1086	   1298	   1058	   509	  
E2AK4	   2475	   1578	   4802	   4145	  
EF2K	   1997	   1980.5	   672.5	   1153	  
EGFR	   1533.5	   156	   15245	   6654	  
EPHA1	   849	   1480	   0	   1931	  
EPHA2	   760.5	   716	   18563	   6723.5	  
EPHA4	   849	   356	   264	   371	  
EPHA6	   0	   147	   0	   0	  
EPHAA	   0	   55	   0	   0	  
EPHB2	   187.5	   59.5	   2982.5	   795.5	  
EPHB3	   2655.5	   920	   0	   1502	  
EPHB4	   3785.5	   3909.5	   1484	   2949	  
EPHB6	   291	   0	   0	   151	  
ERBB2	   206109.5	   4971	   1696	   4477	  
ERBB3	   8882.5	   15739.5	   133.5	   2024	  
ERBB4	   172	   1021	   0	   0	  
ERN1	   201	   420	   2249	   264	  
FAK1	   5112	   3070	   7057	   6399	  
FAK2	   479	   257	   227	   4023	  
FASTK	   1801	   2087	   910	   1019	  
FER	   55	   223	   843	   389	  
FGFR1	   1512	   555.5	   3966	   0	  
FGFR2	   0	   506	   0	   1246	  
FGFR3	   674	   1119	   0	   413	  
FGFR4	   3218	   753	   0	   0	  
FRK	   148	   56	   0	   273	  
FYN	   0	   0	   3684	   1448	  
GAK	   2287	   3272	   1187	   2592	  
GRK5	   0	   0	   393	   80	  
GRK6	   1597	   2539	   3244	   1391	  
	   82	  
GSK3A	   2477	   1867	   3399	   1729	  
GSK3B	   4397	   3160	   1128	   3225	  
HASP	   250.5	   326.5	   622	   260	  
HIPK1	   2209	   12602	   4225	   1407	  
HIPK2	   9324	   1469	   5588	   2423	  
HIPK3	   1266	   1155	   1755	   1833	  
HSPB8	   566	   2244	   527	   0	  
HUNK	   434	   184	   0	   0	  
ICK	   1134	   1198	   2093	   380	  
IGF1R	   1533	   15632	   1755	   4261	  
IKKA	   960	   759	   1830	   590	  
IKKB	   1025	   788.5	   1452	   1432	  
IKKE	   105	   464	   782	   565	  
ILK	   3528	   1549	   5634	   3047	  
INSR	   1144	   1575	   2044	   867	  
IPMK	   242	   105	   386	   138	  
IRAK1	   2998	   7331	   10566	   3939	  
IRAK2	   0	   0	   1306	   242	  
IRAK3	   0	   0	   188	   221	  
IRAK4	   818.5	   445.5	   448	   589	  
JAK1	   3117	   4976	   5942	   4359	  
JAK2	   0	   541	   203	   263	  
JAK3	   0	   59	   0	   0	  
K6PL	   4432.5	   10501.5	   2430.5	   6234.5	  
K6PP	   3482.5	   6835.5	   11110.5	   15336.5	  
KALRN	   532	   600	   0	   334	  
KAPCA	   2909.5	   2557.5	   2665	   2286.5	  
KAPCB	   1874	   277	   554	   518	  
KC1A	   8343	   6521	   7695	   7409.5	  
KC1AL	   209	   143	   186	   207.5	  
KC1D	   5788.5	   3146.5	   3626.5	   4069	  
KC1E	   1933.5	   1422	   6049.5	   3901	  
KC1G1	   1006	   1202	   1058	   1852	  
KC1G2	   1141	   1193.5	   1588	   1297	  
KC1G3	   413	   1054	   2392	   936	  
KCC1A	   0	   149	   913	   55	  
KCC1D	   62	   191	   232.5	   0	  
KCC2B	   719	   342	   0	   0	  
KCC2D	   1910	   704	   1121	   1309	  
KCC2G	   1582	   1203	   443	   2525	  
KGP2	   0	   0	   0	   156	  
	   83	  
KIT	   0	   53	   0	   0	  
KITM	   1079	   193	   1047	   530	  
KKCC1	   852	   141	   400	   199	  
KKCC2	   2155	   2057	   2092	   1764	  
KPCA	   879	   333	   4794.5	   483	  
KPCD	   879	   5191	   2728	   2495	  
KPCD1	   343	   0	   0	   0	  
KPCD2	   933	   1306	   902	   2854	  
KPCD3	   698	   369	   2518	   1324	  
KPCE	   75	   521	   4719	   151	  
KPCI	   2680.5	   1981.5	   4120.5	   2949	  
KPCL	   1776	   1356	   180	   1018	  
KPCT	   0	   0	   0	   349	  
KPCZ	   990.5	   968.5	   826.5	   1297	  
KPSH1	   2016	   1937	   514	   936	  
KPYM	   72572	   72714	   28073	   101218	  
KS6A1	   1917	   809	   1497.5	   4158	  
KS6A2	   384	   343	   770.5	   1032	  
KS6A3	   1212	   826	   3001	   1442.5	  
KS6A4	   1774	   1688	   2391	   2043	  
KS6A5	   1095	   559	   815	   375	  
KS6A6	   249	   0	   0	   0	  
KS6B1	   6419	   22261	   2858	   992	  
KS6B2	   2471	   2167	   1427	   1312	  
KS6C1	   740	   271	   1337	   489	  
KSR1	   0	   189	   171	   66	  
KSR2	   171	   484	   0	   0	  
KSYK	   764.5	   1352.5	   0	   960	  
KT3K	   2334	   1019	   887	   1192	  
LATS1	   697	   791	   1182	   682	  
LATS2	   265	   1218	   2616	   955	  
LIMK1	   884	   1359	   2248	   1780	  
LIMK2	   3432	   804	   378	   5369	  
LMTK2	   1316.5	   1162.5	   1254.5	   1285	  
LMTK3	   0	   213	   0	   328	  
LRRK1	   0	   0	   857	   1298	  
LRRK2	   374	   0	   0	   0	  
LTK	   0	   0	   52	   0	  
LYN	   0	   534	   920	   1246	  
M3K1	   1051	   1526	   847	   542	  
M3K10	   55	   79	   367	   174	  
	   84	  
M3K11	   2000	   2219	   948	   1685	  
M3K12	   0	   361	   155	   183	  
M3K13	   157	   0	   0	   291	  
M3K14	   245	   178	   1935	   566	  
M3K15	   0	   0	   173	   0	  
M3K2	   792	   1282	   1871	   786	  
M3K3	   614	   1879	   1452	   577	  
M3K4	   617	   688	   1082	   1711	  
M3K5	   74	   265	   267	   1011	  
M3K6	   661	   582	   290	   1562	  
M3K7	   1497	   1304	   1185	   1251	  
M3K8	   157	   187	   0	   136	  
M3K9	   711	   1004.5	   419	   1488	  
M3KL4	   0	   260	   938	   278	  
M4K2	   1190	   363	   183	   467	  
M4K3	   1176	   2332	   1459	   829	  
M4K4	   3721	   3772	   9468.5	   11162	  
M4K5	   1079	   1025	   3403	   1319	  
MAPK2	   2296.5	   3969.5	   8424	   2616	  
MAPK3	   832.5	   1722.5	   2348	   5095	  
MAPK5	   1232	   1214	   1189	   723	  
MARK1	   138	   0	   52	   272	  
MARK2	   5191	   2531	   1933	   2828	  
MARK3	   2766	   3918	   3226	   2077	  
MARK4	   523	   726	   721	   1565	  
MAST1	   0	   0	   144	   0	  
MAST2	   3626.5	   1511	   1927.5	   1594.5	  
MAST3	   71	   508.5	   387.5	   631.5	  
MAST4	   219	   915	   398	   3927	  
MASTL	   976	   1035	   1565	   540	  
MATK	   0	   403	   0	   0	  
MELK	   718	   1052	   2065	   982	  
MERTK	   401	   0	   1400	   0	  
MET	   1244	   1264	   11106	   6428	  
MINK1	   2448	   4282	   2945.5	   6486.5	  
MK01	   6126	   3241	   3848	   5074	  
MK03	   2269.5	   5331	   555	   1538	  
MK04	   289.5	   0	   0	   0	  
MK06	   2124	   6223	   4137	   2978	  
MK07	   308	   239	   443	   351	  
MK08	   687	   410.5	   1553	   424	  
	   85	  
MK09	   2695	   3056	   1870	   994	  
MK10	   892	   119.5	   0	   287	  
MK11	   396	   304	   54	   213	  
MK12	   233	   59	   671	   206	  
MK13	   2543	   246	   1564	   1007.5	  
MK14	   2672	   2198	   4207	   2106.5	  
MK15	   0	   147	   0	   0	  
MKNK1	   1287	   574	   626	   1170	  
MKNK2	   2044	   1558	   3257	   8455	  
MLKL	   0	   201	   187	   449	  
MLTK	   787	   1863	   4866	   5231	  
MOK	   58	   149.5	   520	   270.5	  
MP2K1	   1050	   1730	   2883	   2736	  
MP2K2	   1421	   1919	   2738	   2865	  
MP2K3	   797	   1132	   4101	   1275	  
MP2K4	   1573	   1085	   2039	   1141	  
MP2K5	   334	   446	   423	   503	  
MP2K6	   0	   55	   0	   0	  
MP2K7	   686	   726	   2102	   998	  
MRCKA	   3386	   1477	   7975	   2000	  
MRCKB	   6788	   7663	   7837	   6450	  
MRCKG	   2679	   1983	   0	   1917	  
MST4	   423	   1463	   532	   1103	  
MTOR	   3933	   2621	   3820	   3929	  
MUSK	   0	   0	   563	   0	  
MYLK	   120	   0	   2122	   1962	  
MYO3B	   0	   0	   0	   337	  
NDKA	   2065	   3423	   4591	   1862	  
NDKB	   86	   196	   222	   243	  
NDKM	   1900	   2301	   758	   1190	  
NEK1	   279	   233	   1139	   510	  
NEK11	   175	   154	   282	   127	  
NEK2	   565	   552	   1717	   562	  
NEK3	   0	   163	   139	   209	  
NEK4	   415	   848	   835	   519	  
NEK5	   117	   188	   0	   0	  
NEK6	   3761	   1788	   3449	   573	  
NEK7	   1256	   1143	   3234	   1307	  
NEK8	   390	   267	   60	   72	  
NEK9	   3006	   467	   3566	   1820	  
NLK	   755	   593	   642.5	   279	  
	   86	  
NRBP	   3764	   11677	   5601	   3844	  
NRBP2	   538	   377	   683	   996	  
NRK	   1169	   0	   369	   0	  
NTKL	   6076	   3271	   4343	   2152	  
NUAK1	   0	   679	   1688	   244	  
NUAK2	   266	   252	   693	   228	  
OBSCN	   0	   365	   284	   241	  
OXSR1	   1158	   2475	   8680	   2280	  
P3C2A	   2270	   1452	   3209	   1261	  
P3C2B	   1749	   1726	   0	   511	  
P3C2G	   0	   0	   0	   57	  
P55G	   7386	   3899	   156	   585	  
P85A	   1946	   4783	   895	   1781	  
P85B	   3476.5	   4298.5	   1906.5	   2268.5	  
PACE1	   1518	   465	   550	   275	  
PAK1	   564	   170	   906	   2167	  
PAK2	   4112	   5594.5	   7732	   2225	  
PAK4	   3855	   3872	   1348	   1573	  
PAK6	   828	   0	   0	   743.5	  
PAN3	   770	   1567	   1350	   768	  
PASK	   500	   708	   0	   216	  
PCTK1	   5791	   5500	   6025	   6584	  
PCTK2	   502	   718	   2078	   452	  
PCTK3	   0	   475	   0	   671	  
PDK1	   379	   412	   851	   646	  
PDK1L	   653	   478	   430	   169	  
PDK2	   2495	   1272	   640.5	   748	  
PDK3	   804	   716	   0	   134	  
PDPK1	   2571	   3421	   2479	   1488	  
PDXK	   2775	   9525	   3461	   5447	  
PFTK1	   1083	   484	   301	   455	  
PGFRB	   0	   0	   118	   0	  
PHKG2	   1008	   1534	   265	   309	  
PI3R4	   1407	   1684	   703	   994	  
PI42A	   1011	   1721	   3198	   299	  
PI42B	   30686	   1141	   1785	   1601	  
PIM1	   76	   354	   1840	   1566	  
PIM2	   188	   335	   413	   182	  
PIM3	   1389	   2234	   2884	   1278	  
PINK1	   2149	   910	   2258	   5559	  
PK3C3	   963	   368	   1122	   1085	  
	   87	  
PK3CA	   643	   801	   1416	   798	  
PK3CB	   1198	   1643	   872	   1381	  
PK3CD	   0	   114	   928	   399	  
PKN1	   5068	   3733	   15947.5	   968	  
PKN2	   1234	   771	   2870	   1767	  
PKN3	   0	   241	   717.5	   220	  
PLK1	   1402.5	   4340	   2432	   2675	  
PLK2	   3485	   3939	   7671	   9606	  
PLK3	   0	   140	   716	   875	  
PLK4	   338	   672	   1241	   386	  
PMYT1	   854	   1364	   755	   619	  
PRKDC	   7519	   6742	   15372	   10395	  
PRKX	   1067.5	   1086	   712	   1635	  
PRKY	   151.5	   144	   63.5	   253	  
PRP4B	   2976	   3049	   3104	   1387	  
PRPK	   1003	   1320	   1352	   445	  
PTK6	   1144	   1089	   596	   0	  
PTK7	   3679	   758.5	   2290	   8589	  
PXK	   0	   146	   814	   218	  
QSK	   480	   386	   2408	   1541	  
RAF1	   3513	   6106	   4345	   2473	  
RET	   2718	   4807	   0	   0	  
RIOK1	   481	   690	   3221	   463	  
RIOK2	   490	   780	   1532	   383	  
RIOK3	   2064	   1257	   6233	   3990	  
RIPK1	   2001	   1682	   3692	   1446	  
RIPK2	   738	   1296	   1100	   1171	  
RIPK4	   516	   362	   267	   5618	  
RN5A	   324	   451	   0	   465	  
ROCK1	   2637	   2014	   3812	   2180	  
ROCK2	   1660.5	   2090.5	   4477.5	   1591	  
RON	   136	   354	   247	   925	  
ROR1	   0	   0	   1468	   0	  
ROS	   0	   0	   0	   305	  
RPKL1	   281	   402	   241	   0	  
RYK	   1850	   1636	   2074	   2446	  
SBK1	   2112	   769	   0	   0	  
SCYL2	   2372	   1796	   3143	   1818	  
SG196	   155	   0	   136	   264	  
SG223	   1020	   780	   1159	   958	  
SG269	   159	   920	   1477	   888	  
	   88	  
SGK1	   0	   170	   2310	   1754	  
SGK3	   691	   692	   262	   283	  
SIK1	   0	   966	   1883	   3402	  
SIK2	   1010	   531	   1851	   1200	  
SLK	   2452	   1700	   4487	   6123	  
SMG1	   3303	   3792.5	   5899	   2555.5	  
SNRK	   1423	   534	   986	   589	  
SPEG	   0	   425	   0	   923	  
SRC	   311	   877	   2151	   2575	  
SRMS	   500	   79	   0	   0	  
SRPK1	   2039	   1893	   14293	   2872	  
SRPK2	   2555	   3355	   1580	   1882	  
ST17A	   680	   335	   1409	   2392	  
ST17B	   434	   388	   1352	   613	  
ST32C	   0	   383	   1143	   0	  
ST38L	   921	   500	   729	   785	  
STK10	   226	   1701	   4890	   1624	  
STK11	   1010	   1601	   2016	   1813	  
STK16	   1244	   1236	   700	   926	  
STK19	   424	   586	   784	   353	  
STK24	   2679	   3583	   5018	   6527	  
STK25	   1528	   1602	   1468	   1497	  
STK3	   932	   903	   678	   1189	  
STK31	   0	   57	   0	   0	  
STK33	   0	   0	   211	   0	  
STK35	   2761	   1427	   2094	   1433	  
STK36	   478	   934	   206	   426	  
STK38	   2117	   2848	   5966	   1976	  
STK39	   607	   1079	   1763	   3195	  
STK4	   2810.5	   1664	   6437.5	   1490.5	  
STK40	   993	   1064	   7195	   680	  
STK6	   3663	   2861	   3404	   852	  
STRAA	   571	   1325	   373	   915	  
STRAB	   465	   327	   824	   337	  
STYK1	   250	   0	   163	   66	  
TAF1	   968.5	   1461.5	   2465	   1034.5	  
TAF1L	   153.5	   229	   353.5	   167.5	  
TAOK1	   2301	   1287.5	   3099	   1580	  
TAOK2	   2160	   3675	   663	   1662.5	  
TAOK3	   3229	   3199.5	   4059	   2196	  
TBCK	   619	   677	   115	   622	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TBK1	   1479	   1521	   964	   598	  
TEC	   0	   0	   340	   74	  
TESK1	   761	   856	   1257	   655	  
TESK2	   686	   164.5	   119	   253	  
TEX14	   0	   171	   0	   0	  
TGFR1	   2026	   1696	   2935	   1662	  
TGFR2	   866	   647	   8480	   12034	  
TIF1A	   3374	   2884	   1650	   646	  
TIF1B	   12121	   17509	   10068	   9782	  
TITIN	   135	   233	   174	   193	  
TLK1	   2118	   1958	   1702	   1205	  
TLK2	   961	   3599	   3191.5	   997	  
TNIK	   0	   326	   145	   159.5	  
TNK1	   717	   511	   187	   466	  
TOPK	   563	   496	   963	   502	  
TRI33	   1755	   9245	   2826	   1307	  
TRIB1	   2804	   941	   411	   1022	  
TRIB2	   239	   57	   260	   327	  
TRIB3	   6091	   2572	   7292	   920	  
TRIO	   5052	   2403	   19549	   4048	  
TRPM7	   1220	   4061	   1415	   1160	  
TRRAP	   4444	   4134	   3925	   2498	  
TSSK4	   60	   0	   0	   0	  
TTBK2	   0	   165	   577	   299	  
TTK	   734	   661	   1664	   620	  
TXK	   0	   0	   51	   0	  
TYK2	   2149	   1807	   2430	   1489	  
TYRO3	   674	   372	   870	   544	  
UFO	   0	   0	   64735	   2507	  
UHMK1	   1876	   1226	   2346	   1238	  
ULK1	   2892	   5293	   1005	   1238	  
ULK2	   477	   752	   317	   963	  
ULK3	   1316	   1915	   561	   678	  
ULK4	   0	   0	   156	   0	  
VGFR2	   0	   0	   564	   0	  
VRK1	   427	   987	   904	   499	  
VRK2	   644	   529	   662	   859	  
VRK3	   897	   618	   679	   586	  
WEE1	   1818	   611	   1377	   831	  
WNK1	   6040	   4056	   6771	   6994	  
WNK2	   699	   1040	   0	   0	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WNK3	   0	   0	   198	   0	  
WNK4	   196	   0	   187	   0	  
YES	   3787	   1653	   4678	   2343	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APPENDIX 2: RNA-seq RPKM values for expressed kinases with greater than 50 
reads 
 
gene	   BT-­‐474	   MCF-­‐7	   MDA	   HuMEC	  
AAK1	   12.19190333	   13.35276743	   31.49870723	   37.84842907	  
AAPK1	   12.69394572	   11.84785014	   18.50201005	   9.659740737	  
AAPK2	   3.03991999	   0	   10.06686739	   0	  
ABL1	   56.60880947	   27.83069823	   33.65560106	   17.00490972	  
ABL2	   6.344465937	   10.91280069	   240.676735	   25.03303177	  
ACK1	   7.985229854	   20.55884979	   10.9844439	   11.03069256	  
ACV1B	   30.66500071	   41.01153499	   15.79587984	   22.41682701	  
ACVR1	   7.241870878	   11.15347926	   11.11482164	   10.32042905	  
ADCK1	   7.324419097	   8.290205201	   0	   2.059236938	  
ADCK2	   14.2427894	   33.61629027	   7.45175141	   14.52016936	  
ADCK3	   8.867493722	   14.73849973	   18.20441397	   10.91824496	  
ADCK4	   5.228859142	   8.312591501	   1.039165715	   8.437810343	  
ADCK5	   5.812485395	   5.501479189	   3.593811247	   6.329049003	  
AKT1	   154.8927907	   221.2359953	   48.32674297	   56.31459388	  
AKT2	   102.7588758	   107.5802336	   70.41745678	   74.84480252	  
AKT3	   0	   0	   30.49426203	   9.804874106	  
ALPK1	   2.223471942	   2.361437301	   1.118573034	   7.293059059	  
ALPK2	   0	   0	   0.870912447	   0	  
ALPK3	   1.252017648	   0.94315429	   0	   0.300985848	  
ARAF	   44.41902226	   39.57436032	   28.26544589	   28.10096392	  
ARBK1	   47.37433745	   49.47446111	   23.65167737	   30.87870122	  
ARBK2	   2.588360429	   1.989239096	   5.586309188	   7.541728832	  
ATM	   4.709679363	   3.563968565	   10.25314849	   4.75185085	  
ATR	   5.145651361	   7.90981487	   5.116252995	   4.563729876	  
AURKB	   19.23613033	   40.21023958	   56.65319323	   21.63070779	  
AVR2A	   6.77889855	   7.168522912	   5.730632569	   5.916555143	  
AVR2B	   4.562171717	   21.12556869	   18.48551545	   7.239705117	  
BCKD	   31.97186332	   50.34653945	   33.74866816	   39.14957012	  
BCR	   45.74038531	   50.36141317	   13.9907966	   53.99874088	  
BMP2K	   5.159127925	   4.462224972	   21.50086581	   7.28212828	  
BMPR2	   17.95981487	   21.54113392	   12.83982422	   26.38315343	  
BMR1A	   4.321499213	   4.043725234	   4.187647759	   2.766670724	  
BMR1B	   0	   4.177558324	   6.634504187	   2.80170645	  
BRAF1	   6.189936869	   4.646259234	   8.157247177	   4.589615528	  
BRD2	   59.49440698	   69.73221352	   105.3957106	   35.90990246	  
BRD3	   22.98437262	   22.05141445	   11.00210006	   7.168322106	  
BRD4	   38.52995735	   18.6357988	   56.03276557	   18.15573943	  
BRSK1	   0	   0	   5.482232784	   0	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BRSK2	   0	   1.084053575	   0	   0	  
BUB1	   11.48725425	   20.14779979	   46.50954256	   16.40304454	  
BUB1B	   10.23298613	   10.78009658	   17.95262897	   10.62970396	  
CCRK	   3.565532976	   8.187888568	   0	   2.257979917	  
CD11A	   14.64232556	   14.61415553	   12.92066931	   14.75647742	  
CD11B	   16.25203356	   15.57328274	   14.05324759	   16.3521418	  
CD2L5	   20.39627446	   18.50389619	   14.92098525	   13.12512973	  
CD2L6	   17.35373492	   18.56649386	   5.399197223	   6.918136669	  
CD2L7	   81.04662177	   13.09228569	   24.10308869	   13.99600604	  
CDC2	   28.49706785	   34.61124452	   59.76130746	   18.74810429	  
CDC7	   4.720173119	   3.530742515	   4.963409492	   2.224707219	  
CDK10	   18.06959542	   30.97927511	   12.82970634	   17.07384563	  
CDK2	   31.47106203	   36.73055637	   35.39903886	   16.43316129	  
CDK3	   3.060070975	   1.595535525	   0	   0	  
CDK4	   132.3041463	   217.5789759	   163.4907143	   44.71849012	  
CDK5	   30.81358425	   37.37655934	   7.921790259	   20.37731198	  
CDK6	   1.326071947	   3.567620256	   15.03413165	   13.016781	  
CDK7	   12.98244841	   27.04440467	   48.85106791	   39.59074186	  
CDK8	   8.798438572	   15.77943916	   12.26147638	   14.32036026	  
CDK9	   36.61485156	   48.43613388	   55.3182951	   31.38796143	  
CDKL1	   0	   0	   9.617553994	   0	  
CDKL2	   0	   0	   0	   1.102461522	  
CDKL5	   3.08233591	   2.010494377	   1.139670651	   1.85976228	  
CHK1	   13.31309043	   9.879677342	   23.77346657	   10.83944384	  
CHK2	   5.466648532	   12.38886408	   3.832421895	   4.77728968	  
CHKA	   17.79158847	   11.42843478	   16.95049162	   1.71968811	  
CLK1	   14.27163536	   11.85791276	   20.93637887	   8.801794319	  
CLK2	   13.7714343	   23.23242342	   11.54787156	   9.215168797	  
CLK3	   22.89760834	   31.57366381	   28.80192366	   18.71555207	  
CLK4	   6.05670368	   6.438001475	   9.425855419	   3.101763332	  
CSK	   35.19384599	   69.74282118	   21.25476361	   36.21073777	  
CSK21	   33.13851695	   21.32406085	   52.10265156	   27.70876773	  
CSK22	   24.28695882	   12.09960028	   29.61770732	   41.53580188	  
CSKP	   28.6151662	   18.47270987	   29.86797756	   23.24382063	  
CTRO	   6.589900574	   6.992757627	   9.340411176	   6.384439286	  
DAPK1	   0	   0.428249055	   1.872501756	   11.72940324	  
DAPK2	   2.984153475	   2.756557816	   0	   6.153982802	  
DAPK3	   18.698772	   19.67749506	   24.85572702	   18.91794033	  
DCK	   12.42977154	   13.53598587	   18.23665879	   8.506340783	  
DCLK1	   9.481124132	   6.742253559	   0	   0	  
DCLK2	   2.364322211	   0	   2.301045556	   0	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DDR1	   93.19762513	   146.7797189	   8.096508933	   161.84604	  
DDR2	   0	   0	   0.540923017	   0	  
DMPK	   13.49689243	   10.16204308	   7.586728137	   4.987311225	  
DUSTY	   6.838127121	   14.93192167	   9.104136183	   12.31990479	  
DYR1A	   11.05080093	   12.43605975	   17.1386953	   8.089442267	  
DYR1B	   5.112583048	   9.276596964	   1.925456839	   3.875896476	  
DYRK2	   7.68130775	   10.87522325	   5.068191917	   10.48541296	  
DYRK3	   0	   0	   8.51954424	   1.348991622	  
DYRK4	   5.229232445	   0	   5.135067761	   6.924823661	  
E2AK1	   127.9883431	   127.7737544	   29.38959682	   50.26985478	  
E2AK2	   12.37152113	   19.72173661	   13.17937924	   14.73136118	  
E2AK3	   8.819649046	   10.83558083	   7.968779215	   4.170716983	  
E2AK4	   19.13129952	   12.53811624	   34.42516824	   32.32698949	  
EF2K	   19.4302529	   19.80757278	   6.068443673	   11.31882005	  
EGFR	   18.80038506	   1.9659098	   173.3385027	   82.30708485	  
EPHA1	   9.783636712	   17.53114849	   0	   22.45155166	  
EPHA2	   6.812554138	   6.592950203	   154.2210163	   60.76837412	  
EPHA4	   9.613321953	   4.143542713	   2.772390307	   4.238490031	  
EPHA6	   0	   3.756114204	   0	   0	  
EPHAA	   0	   0.953774221	   0	   0	  
EPHB2	   1.903411828	   0.620875442	   28.07996693	   8.147852063	  
EPHB3	   22.08680082	   7.865572916	   0	   12.60456613	  
EPHB4	   46.49056325	   49.35359579	   16.90285657	   36.54161935	  
EPHB6	   3.004458919	   0	   0	   1.572974521	  
ERBB2	   1744.025645	   43.23690965	   13.30961071	   38.22200024	  
ERBB3	   71.19843267	   129.6827389	   0.992432849	   16.36881291	  
ERBB4	   1.502456698	   9.167592159	   0	   0	  
ERN1	   2.055307971	   4.414547199	   21.32823673	   2.723680963	  
FAK1	   45.26226001	   27.94086137	   57.94956168	   57.1648357	  
FAK2	   4.092565389	   2.257092003	   1.798749221	   34.68020098	  
FASTK	   37.87955184	   45.1200522	   17.75076848	   21.62403635	  
FER	   1.19692448	   4.988442242	   17.01438605	   8.541322515	  
FGFR1	   17.46971412	   6.59741943	   42.49828109	   0	  
FGFR2	   0	   5.906554456	   0	   14.27634953	  
FGFR3	   5.966172741	   10.18174084	   0	   3.688564975	  
FGFR4	   41.35747334	   9.947614805	   0	   0	  
FRK	   1.992485762	   0.774956925	   0	   3.708238152	  
FYN	   0	   0	   58.91431479	   25.1916482	  
GAK	   19.26823169	   28.33642225	   9.274939005	   22.03343212	  
GRK5	   0	   0	   5.937943108	   1.31498343	  
GRK6	   21.31211847	   34.82895398	   40.15015248	   18.72924604	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GSK3A	   39.74548816	   30.79372109	   50.5821915	   27.99163598	  
GSK3B	   92.31411597	   68.19534914	   21.96369464	   68.3144896	  
HASP	   3.145740214	   4.214580319	   7.244195409	   3.294275615	  
HIPK1	   20.25308355	   118.7656743	   35.92582911	   13.01550416	  
HIPK2	   81.87472682	   13.25944725	   45.5080938	   21.46705518	  
HIPK3	   10.06504184	   9.438867469	   12.94027923	   14.70333334	  
HSPB8	   11.81244789	   48.13958612	   10.20043605	   0	  
HUNK	   2.064176457	   0.899561663	   0	   0	  
ICK	   10.99391338	   11.93856421	   18.81885226	   3.71701499	  
IGF1R	   11.91273032	   124.8647141	   12.64826408	   33.40812864	  
IKKA	   9.612121212	   7.811704504	   16.99353551	   5.960346075	  
IKKB	   15.31365387	   12.10912282	   20.11899236	   21.58586411	  
IKKE	   1.447997942	   6.577375725	   10.00161301	   7.861375714	  
ILK	   70.77013447	   31.93955693	   104.8148784	   61.66878017	  
INSR	   4.453307227	   6.302215018	   7.379419041	   3.405235796	  
IPMK	   4.657577474	   2.077256113	   6.889959583	   2.679756096	  
IRAK1	   30.73631938	   77.25729112	   100.4651614	   40.74531429	  
IRAK2	   0	   0	   19.4797232	   3.926827121	  
IRAK3	   0	   0	   2.63860844	   3.374397053	  
IRAK4	   17.57288127	   9.83168656	   8.920453898	   12.75883571	  
JAK1	   31.04123081	   50.93760573	   54.88067271	   43.79862325	  
JAK2	   0	   4.999395206	   1.692563087	   2.385565729	  
JAK3	   0	   0.739387951	   0	   0	  
K6PL	   53.48279918	   130.2485049	   27.19854416	   75.8994229	  
K6PP	   46.56275224	   93.94503453	   137.7735247	   206.8927328	  
KALRN	   3.232893398	   3.747891653	   0	   2.047847811	  
KAPCA	   39.48768558	   35.67918997	   33.54479791	   31.31021023	  
KAPCB	   35.33168274	   5.368222768	   9.686996621	   9.853623286	  
KC1A	   207.8311886	   166.9777878	   177.7795285	   186.2296554	  
KC1AL	   3.030956739	   2.131697197	   2.501675894	   3.036148519	  
KC1D	   110.0795721	   61.50698744	   63.960673	   78.07281603	  
KC1E	   48.75292203	   36.85633065	   141.4687783	   99.24391402	  
KC1G1	   16.1642446	   19.85262438	   15.76622603	   30.02409148	  
KC1G2	   19.81058736	   21.30051756	   25.57094945	   22.72077512	  
KC1G3	   5.611734228	   14.72121579	   30.1434437	   12.83200001	  
KCC1A	   0	   3.884186822	   21.47401453	   1.407317104	  
KCC1D	   1.234527303	   3.909294621	   4.29355089	   0	  
KCC2B	   12.060347	   5.89675446	   0	   0	  
KCC2D	   26.59032877	   10.07439614	   14.47373445	   18.38660076	  
KCC2G	   15.09142624	   11.79629049	   3.919333147	   24.30281876	  
KGP2	   0	   0	   0	   2.72069554	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KIT	   0	   0.369553601	   0	   0	  
KITM	   31.82125279	   5.850717961	   28.6369762	   15.77041631	  
KKCC1	   8.479993646	   1.442550647	   3.692330531	   1.998391013	  
KKCC2	   27.75682115	   27.23408379	   24.99014527	   22.92411048	  
KPCA	   10.27771421	   4.002284166	   51.99189334	   5.698049954	  
KPCD	   14.27381114	   86.64791663	   41.08469667	   40.8783239	  
KPCD1	   3.274703038	   0	   0	   0	  
KPCD2	   11.01915444	   15.85498474	   9.880019728	   34.00885845	  
KPCD3	   4.83851519	   2.629293558	   16.18814403	   9.260109682	  
KPCE	   0.901856203	   6.439761478	   52.62724781	   1.831995659	  
KPCI	   41.09588267	   31.22716823	   58.5891325	   45.61721141	  
KPCL	   30.39997283	   23.85865453	   2.857507553	   17.58123874	  
KPCT	   0	   0	   0	   5.528896916	  
KPCZ	   18.21498018	   18.30753501	   14.09618949	   24.06498851	  
KPSH1	   20.19696935	   19.94717163	   4.775770468	   9.461129498	  
KPYM	   1094.478397	   1127.229025	   392.655401	   1540.165224	  
KS6A1	   24.56522056	   10.65621812	   17.79713251	   53.75941069	  
KS6A2	   2.778683248	   2.551279054	   5.170887742	   7.534578729	  
KS6A3	   18.82823664	   13.18994852	   43.23721093	   22.60967446	  
KS6A4	   24.6092005	   24.06979306	   30.76154281	   28.59457955	  
KS6A5	   13.77546589	   7.228696806	   9.508990931	   4.759867941	  
KS6A6	   3.421732762	   0	   0	   0	  
KS6B1	   112.8442624	   402.265513	   46.59710966	   17.59524175	  
KS6B2	   50.02428117	   45.09444516	   26.79271549	   26.79868018	  
KS6C1	   7.356913889	   2.769422836	   12.32764184	   4.905059406	  
KSR1	   0	   1.499074326	   1.223731376	   0.513831509	  
KSR2	   2.412150237	   7.017939664	   0	   0	  
KSYK	   10.04959654	   18.27529666	   0	   12.73250423	  
KT3K	   48.4802482	   21.75675854	   17.08725303	   24.98110804	  
LATS1	   5.772608388	   6.733980068	   9.07907163	   5.698954008	  
LATS2	   1.927907545	   9.108432461	   17.65073183	   7.00995387	  
LIMK1	   12.00227095	   18.9664759	   28.30688735	   24.3838694	  
LIMK2	   45.06413957	   10.8516525	   4.603204318	   71.12932175	  
LMTK2	   6.863757109	   6.230028447	   6.065915508	   6.759516465	  
LMTK3	   0	   1.546721417	   0	   2.33787762	  
LRRK1	   0	   0	   4.618242729	   7.609523055	  
LRRK2	   1.69831746	   0	   0	   0	  
LTK	   0	   0	   0.564079413	   0	  
LYN	   0	   11.31449779	   17.58775776	   25.91358515	  
M3K1	   4.907688363	   7.324615304	   3.668109736	   2.553553771	  
M3K10	   0.559466004	   0.826026782	   3.462276311	   1.785795482	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M3K11	   19.74384088	   22.51723052	   8.679498491	   16.78313204	  
M3K12	   0	   3.873341142	   1.50050991	   1.927281138	  
M3K13	   2.009662533	   0	   0	   3.758269607	  
M3K14	   1.932940649	   1.443538802	   14.15852631	   4.505472315	  
M3K15	   0	   0	   1.199824653	   0	  
M3K2	   8.797735611	   14.63827073	   19.27543378	   8.809266131	  
M3K3	   9.184972683	   28.89297774	   20.14469805	   8.708768989	  
M3K4	   4.018484839	   4.605975605	   6.535654398	   11.24342531	  
M3K5	   0.567758339	   2.089939437	   1.899886739	   7.826262621	  
M3K6	   6.290207973	   5.693017974	   2.559447297	   14.99740205	  
M3K7	   19.07184132	   17.07671934	   14.00147608	   16.08050167	  
M3K8	   3.082456115	   3.773939046	   0	   2.694062196	  
M3K9	   7.784717043	   11.30522466	   4.254728984	   16.43794873	  
M3KL4	   0	   2.3357102	   7.602861351	   2.451352913	  
M4K2	   17.04645538	   5.345025417	   2.431212177	   6.749560036	  
M4K3	   16.11005011	   32.8378066	   18.53657572	   11.45817787	  
M4K4	   32.28693033	   33.64300621	   76.1961307	   97.71934882	  
M4K5	   8.79125773	   8.584390357	   25.71438634	   10.84290924	  
MAPK2	   26.68307599	   47.40905238	   90.77629421	   30.66751896	  
MAPK3	   11.752803	   24.99611247	   30.74255474	   72.57263004	  
MAPK5	   21.00637325	   21.27722969	   18.80212227	   12.43798781	  
MARK1	   1.22681661	   0	   0.428734619	   2.439725269	  
MARK2	   59.08302158	   29.61146123	   20.404604	   32.47600004	  
MARK3	   29.46733219	   42.90511793	   31.87407971	   22.3252638	  
MARK4	   6.030861852	   8.605385635	   7.710767428	   18.20805233	  
MAST1	   0	   0	   1.310669014	   0	  
MAST2	   22.20293678	   9.509183541	   10.94464742	   9.849602944	  
MAST3	   0.423184252	   3.115430962	   2.142039643	   3.797658981	  
MAST4	   1.013868479	   4.354262683	   1.708855051	   18.34297893	  
MASTL	   10.29468766	   11.22172785	   15.30954723	   5.746832991	  
MATK	   0	   6.726856174	   0	   0	  
MELK	   11.23351551	   16.91854497	   29.96373511	   15.50151669	  
MERTK	   4.737585424	   0	   15.34000019	   0	  
MET	   20.54283987	   21.45572527	   170.0914242	   107.0994962	  
MINK1	   17.41982761	   31.32096451	   19.43909823	   46.5708668	  
MK01	   142.7812996	   77.64784271	   83.17906792	   119.3208286	  
MK03	   45.03648746	   108.7424295	   10.2143787	   30.79371734	  
MK04	   4.036714094	   0	   0	   0	  
MK06	   19.62230357	   59.09507715	   35.44587053	   27.75822111	  
MK07	   3.752439203	   2.993070001	   5.005544449	   4.314609784	  
MK08	   17.37249046	   10.67024844	   36.42180362	   10.81789248	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MK09	   53.12007264	   61.91690875	   34.18425703	   19.76777251	  
MK10	   12.56249771	   1.729956057	   0	   4.078162224	  
MK11	   9.878707387	   7.795330707	   1.249347763	   5.361125805	  
MK12	   5.105402528	   1.3288688	   13.63581926	   4.554206805	  
MK13	   59.66671805	   5.933035163	   34.03354487	   23.85076451	  
MK14	   58.91532374	   49.81676568	   86.02981216	   46.86242276	  
MK15	   0	   2.793362826	   0	   0	  
MKNK1	   17.44691818	   7.998491635	   7.870442649	   16.00285605	  
MKNK2	   46.34864735	   36.31446506	   68.49495414	   193.4377554	  
MLKL	   0	   3.823520868	   3.209501898	   8.383573628	  
MLTK	   10.50658249	   25.56557838	   60.24811935	   70.46004591	  
MOK	   0.941844193	   2.495446645	   7.831393794	   4.431898442	  
MP2K1	   23.49076916	   39.7841484	   59.81873551	   61.75832243	  
MP2K2	   28.91750884	   40.14188837	   51.6755242	   58.82512854	  
MP2K3	   13.79017806	   20.13325548	   65.80910278	   22.25836177	  
MP2K4	   39.01872371	   27.66496342	   46.90792378	   28.55626746	  
MP2K5	   6.60186485	   9.061728507	   7.754346046	   10.03135517	  
MP2K6	   0	   1.277014744	   0	   0	  
MP2K7	   15.78981976	   17.1769362	   44.87148231	   23.17688456	  
MRCKA	   15.403556	   6.906699459	   33.64723471	   9.179848062	  
MRCKB	   35.55909029	   41.26327164	   38.07529729	   34.09101897	  
MRCKG	   19.55079592	   14.87546218	   0	   14.11514361	  
MST4	   6.516480662	   23.16717582	   7.600970092	   17.14429833	  
MTOR	   17.16285801	   11.7567886	   15.46014896	   17.29892642	  
MUSK	   0	   0	   7.229032314	   0	  
MYLK	   1.438537594	   0	   23.59228455	   23.73069364	  
MYO3B	   0	   0	   0	   2.192157996	  
NDKA	   98.01576338	   167.0085844	   202.1006971	   89.1716919	  
NDKB	   4.390536616	   10.28563831	   10.51130831	   12.51690296	  
NDKM	   66.14088857	   82.33586794	   24.47204586	   41.79601199	  
NEK1	   2.022219919	   1.735945661	   7.656539946	   3.729630573	  
NEK11	   2.906265372	   2.628899384	   4.343411481	   2.1280038	  
NEK2	   11.31426768	   11.36247928	   31.88841582	   11.35496439	  
NEK3	   0	   2.681122735	   2.062873107	   3.374355316	  
NEK4	   5.2320824	   10.98951069	   9.763321752	   6.601844575	  
NEK5	   1.393537563	   2.301689265	   0	   0	  
NEK6	   54.72347378	   26.74199875	   46.54233492	   8.411944645	  
NEK7	   16.94817976	   15.85388406	   40.47231866	   17.79428202	  
NEK8	   6.249303943	   4.397788376	   0.891667503	   1.164048288	  
NEK9	   34.54961536	   5.51730695	   38.01195683	   21.10557011	  
NLK	   9.724547548	   7.851148122	   7.675032664	   3.625752167	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NRBP	   60.64579752	   193.3919543	   83.69534761	   62.48933965	  
NRBP2	   10.60430393	   7.638309751	   12.48547997	   19.8075467	  
NRK	   24.33924033	   0	   7.125306031	   0	  
NTKL	   83.7579293	   46.34946611	   55.52424273	   29.93104592	  
NUAK1	   0	   3.594060143	   8.061514346	   1.267712658	  
NUAK2	   2.746343892	   2.674421451	   6.635767541	   2.375087356	  
OBSCN	   0	   8.298621978	   5.825860488	   5.378307071	  
OXSR1	   8.996666935	   19.76534102	   62.5428196	   17.87225655	  
P3C2A	   21.63694571	   14.22632545	   28.36772207	   12.12709122	  
P3C2B	   8.29830992	   8.41776229	   0	   2.446201345	  
P3C2G	   0	   0	   0	   0.442693797	  
P55G	   49.94763719	   27.1028465	   0.978396502	   3.991470931	  
P85A	   26.57537871	   67.14180805	   11.3355947	   24.53985573	  
P85B	   31.03955373	   39.44992583	   15.78682128	   20.43541576	  
PACE1	   18.55207956	   5.841572951	   6.23401961	   3.390978061	  
PAK1	   9.706076047	   3.00724999	   14.46030427	   37.62659826	  
PAK2	   60.40614493	   84.47832953	   105.3427151	   32.978393	  
PAK4	   55.76777152	   57.57716561	   18.08562194	   22.95932365	  
PAK6	   10.69618041	   0	   0	   9.690603295	  
PAN3	   12.04172108	   25.18969216	   19.58016084	   12.117988	  
PASK	   3.876853524	   5.642852148	   0	   1.68979725	  
PCTK1	   96.76725992	   94.46992995	   93.37198207	   111.0033691	  
PCTK2	   6.042630244	   8.883881812	   23.19810416	   5.489492514	  
PCTK3	   0	   7.492235717	   0	   10.38857017	  
PDK1	   8.544356239	   9.547581586	   17.79321167	   14.69413801	  
PDK1L	   5.342688862	   4.020042307	   3.26287026	   1.395098482	  
PDK2	   41.83060184	   21.92131989	   9.959266302	   12.65309068	  
PDK3	   17.66099532	   16.16695294	   0	   2.969855948	  
PDPK1	   47.13181478	   64.46458408	   42.14763986	   27.52241102	  
PDXK	   58.71681499	   207.1669689	   67.91813465	   116.2862424	  
PFTK1	   9.872724953	   4.535341231	   2.544835562	   4.184961216	  
PGFRB	   0	   0	   0.708295405	   0	  
PHKG2	   22.53678375	   35.25435635	   5.494927001	   6.970458474	  
PI3R4	   10.1980768	   12.54649139	   4.725678299	   7.269123116	  
PI42A	   24.22282412	   42.38483683	   71.06188566	   7.227968778	  
PI42B	   861.5699863	   32.93001665	   46.48075236	   45.35373646	  
PIM1	   1.024739448	   4.90635705	   23.00924316	   21.30409451	  
PIM2	   3.151965189	   5.773303586	   6.421821987	   3.078693187	  
PIM3	   22.19637984	   36.69603119	   42.74248878	   20.60545532	  
PINK1	   29.30205959	   12.75437404	   28.55422105	   76.47682777	  
PK3C3	   11.34676085	   4.457070033	   12.26092171	   12.89872584	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PK3CA	   6.721702486	   8.607100108	   13.72828272	   8.416715817	  
PK3CB	   13.08423599	   18.44527519	   8.832683796	   15.21796877	  
PK3CD	   0	   1.051592901	   7.723593232	   3.612693555	  
PKN1	   59.57493861	   45.10669553	   173.8618338	   11.48084395	  
PKN2	   13.75107153	   8.831445328	   29.66114598	   19.86686728	  
PKN3	   0	   2.894620822	   7.775443458	   2.593658269	  
PLK1	   22.89118069	   72.81336098	   36.81404527	   44.05148662	  
PLK2	   44.44740772	   51.63993184	   90.73613691	   123.6111641	  
PLK3	   0	   2.133666755	   9.845554941	   13.0894694	  
PLK4	   3.740394143	   7.64409307	   12.73670522	   4.309822977	  
PMYT1	   15.31978864	   25.15158151	   12.56106615	   11.20358495	  
PRKDC	   19.6854173	   18.14384446	   37.32497836	   27.45873299	  
PRKX	   8.923175322	   9.331197738	   5.519709022	   13.7892536	  
PRKY	   5.945620535	   5.809022683	   2.311228735	   10.01789639	  
PRP4B	   30.27219686	   31.88045137	   29.28312172	   14.23504789	  
PRPK	   27.87157105	   37.70426445	   34.84350666	   12.47647748	  
PTK6	   21.79077609	   21.32212959	   10.52876861	   0	  
PTK7	   32.37841987	   6.861790793	   18.6915791	   76.26757273	  
PXK	   0	   3.224027327	   16.21805938	   4.725173792	  
QSK	   4.552973429	   3.763545823	   21.18336791	   14.74782503	  
RAF1	   44.36952214	   79.27192903	   50.89569279	   31.5139018	  
RET	   27.94725649	   50.80656993	   0	   0	  
RIOK1	   9.401661046	   13.8632364	   58.38951745	   9.130865884	  
RIOK2	   7.683439079	   12.5721687	   22.27937407	   6.059402553	  
RIOK3	   29.85854226	   18.69176063	   83.62587653	   58.23757238	  
RIPK1	   21.48691842	   18.56560315	   36.76828613	   15.66631299	  
RIPK2	   13.72972891	   24.7837276	   18.97941987	   21.98031718	  
RIPK4	   7.391572248	   5.330300829	   3.547178422	   81.1970627	  
RN5A	   3.063329989	   4.383099598	   0	   4.435812544	  
ROCK1	   22.60745923	   17.74831458	   30.30952752	   18.85686881	  
ROCK2	   15.83167438	   20.48774527	   39.59207025	   15.3048687	  
RON	   2.611757156	   6.988004437	   4.399218026	   17.92285029	  
ROR1	   0	   0	   16.87997191	   0	  
ROS	   0	   0	   0	   1.466201173	  
RPKL1	   3.987849016	   5.864276855	   3.172006567	   0	  
RYK	   22.11706669	   20.10458549	   22.9958358	   29.50419102	  
SBK1	   14.80688756	   5.541817624	   0	   0	  
SCYL2	   21.82158796	   16.98376703	   26.8164136	   16.87473668	  
SG196	   4.869647052	   0	   3.962683105	   8.368375768	  
SG223	   7.742982232	   6.086375163	   8.15973726	   7.337448389	  
SG269	   0.482443208	   2.869412096	   4.156370135	   2.718526041	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SGK1	   0	   2.576741071	   31.59093363	   26.09557567	  
SGK3	   7.525856253	   7.74711479	   2.646450717	   3.109823682	  
SIK1	   0	   7.411204876	   13.03438773	   25.6189565	  
SIK2	   12.11182515	   6.545438775	   20.58634684	   14.51914105	  
SLK	   15.30018942	   10.90388565	   25.96671787	   38.54890628	  
SMG1	   10.51246281	   12.40730657	   17.41241233	   8.206221656	  
SNRK	   9.724098996	   3.750954133	   6.24893539	   4.060983507	  
SPEG	   0	   11.83075796	   0	   25.21974987	  
SRC	   2.785936012	   8.075443196	   17.87046308	   23.27337895	  
SRMS	   11.58452933	   1.881444906	   0	   0	  
SRPK1	   20.9840121	   20.02524975	   136.4204079	   29.82134295	  
SRPK2	   26.28663399	   35.48073626	   15.07598889	   19.53597776	  
ST17A	   10.83689619	   5.487781766	   20.82531798	   38.46171408	  
ST17B	   9.369356565	   8.610091925	   27.06957125	   13.35217364	  
ST32C	   0	   6.458709067	   17.39088974	   0	  
ST38L	   22.18756776	   12.38158079	   16.28779305	   19.0805629	  
STK10	   1.804931833	   13.96409209	   36.21978537	   13.0860884	  
STK11	   15.94406106	   25.97914968	   29.51567712	   28.87665197	  
STK16	   31.05516731	   31.7166996	   16.20675926	   23.32361904	  
STK19	   9.882349172	   14.03938162	   16.9470866	   8.301192843	  
STK24	   42.04556781	   57.802995	   73.04034455	   103.3552592	  
STK25	   33.64885241	   36.26314277	   29.98179336	   33.26137226	  
STK3	   14.17749719	   14.11976384	   9.56528687	   18.24891178	  
STK31	   0	   0.631278315	   0	   0	  
STK33	   0	   0	   2.703953056	   0	  
STK35	   47.65512176	   25.31763737	   33.52003799	   24.9551869	  
STK36	   3.435525275	   6.90030286	   1.373147276	   3.089202019	  
STK38	   20.69527641	   28.61846812	   54.09016052	   19.4898624	  
STK39	   6.926720536	   12.65658222	   18.65846599	   36.78589246	  
STK4	   64.31063536	   39.13889478	   136.6158538	   34.41142445	  
STK40	   9.579352617	   10.55077993	   64.37279375	   6.618617506	  
STK6	   60.26242857	   48.38197514	   51.93784315	   14.14232343	  
STRAA	   8.890058184	   21.20510359	   5.385945753	   14.37345086	  
STRAB	   7.671581124	   5.545436119	   12.60792999	   5.609618018	  
STYK1	   6.667481574	   0	   4.031754393	   1.775976482	  
TAF1	   4.473093715	   6.938462043	   10.55868767	   4.820702454	  
TAF1L	   0.86695272	   1.329469998	   1.851659381	   0.954494224	  
TAOK1	   18.83500304	   10.83308969	   23.52639043	   13.04901175	  
TAOK2	   17.30181818	   30.25877634	   4.925339473	   13.43603437	  
TAOK3	   37.40644521	   38.09925935	   43.60959895	   25.66741832	  
TBCK	   6.466965296	   7.270337553	   1.114274956	   6.556494866	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TBK1	   19.47107543	   20.58292087	   11.77018928	   7.943180082	  
TEC	   0	   0	   5.461390176	   1.293131881	  
TESK1	   10.4453251	   12.07722325	   16.00137231	   9.070893417	  
TESK2	   10.35464759	   2.55230831	   1.665876557	   3.853037074	  
TEX14	   0	   1.26618169	   0	   0	  
TGFR1	   17.62740091	   15.16808361	   23.6832661	   14.58986656	  
TGFR2	   8.809046533	   6.765054783	   80.00028098	   123.5072576	  
TIF1A	   30.33257342	   26.65111973	   13.75728617	   5.859602514	  
TIF1B	   143.6859786	   213.350324	   110.6888292	   116.9970892	  
TITIN	   0.057674656	   0.102320627	   0.068942201	   0.083191703	  
TLK1	   21.81620306	   20.73107983	   16.25913418	   12.52309623	  
TLK2	   7.772149552	   29.91958965	   23.93851786	   8.135502425	  
TNIK	   0	   2.671992919	   1.072295116	   1.283198445	  
TNK1	   9.020099581	   6.60798581	   2.181817551	   5.914929228	  
TOPK	   11.55755518	   10.46635069	   18.33447658	   10.39759166	  
TRI33	   17.56214647	   95.09625506	   26.22752318	   13.19615843	  
TRIB1	   28.29316788	   9.759986471	   3.846183824	   10.40461279	  
TRIB2	   2.940352368	   0.720829179	   2.966603288	   4.059015315	  
TRIB3	   100.8684904	   43.78183009	   111.9948958	   15.37185251	  
TRIO	   23.36070667	   11.42174422	   83.83624709	   18.88576571	  
TRPM7	   5.906497226	   20.20966843	   6.353474066	   5.666300757	  
TRRAP	   12.3922164	   11.84953849	   10.15077608	   7.02811456	  
TSSK4	   1.667292386	   0	   0	   0	  
TTBK2	   0	   1.230333288	   3.881890373	   2.188393686	  
TTK	   8.645617375	   8.003085117	   18.17765771	   7.36822875	  
TXK	   0	   0	   0.647954326	   0	  
TYK2	   17.86981664	   15.44535371	   18.74021644	   12.49251381	  
TYRO3	   6.306279551	   3.577768921	   7.549483195	   5.135511207	  
UFO	   0	   0	   527.7228646	   22.23350356	  
UHMK1	   42.95513268	   28.85550811	   49.81898632	   28.60054671	  
ULK1	   19.40761466	   36.51167788	   6.25496065	   8.382353584	  
ULK2	   4.269696159	   6.919145406	   2.631615901	   8.697137542	  
ULK3	   28.32326562	   42.36549054	   11.19785773	   14.72273819	  
ULK4	   0	   0	   1.250440805	   0	  
VGFR2	   0	   0	   5.917111293	   0	  
VRK1	   8.954073481	   21.27482306	   17.58109244	   10.5575898	  
VRK2	   12.00002369	   10.1322975	   11.44033846	   16.14956613	  
VRK3	   17.06743811	   12.0870521	   11.98202761	   11.24980434	  
WEE1	   19.32686578	   6.676744958	   13.57644736	   8.913331011	  
WNK1	   20.56521222	   14.19548478	   21.38128088	   24.02665677	  
WNK2	   3.592607661	   5.494421594	   0	   0	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WNK3	   0	   0	   0.842252031	   0	  
WNK4	   1.758008533	   0	   1.555575741	   0	  
YES	   28.3918244	   12.73875174	   32.52691394	   17.72318388	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APPENDIX 3: RNA-seq read counts for expressed kinases in TNBC 
 
gene	   Patient	  18	   SUM159	   MDA-­‐MB-­‐231	  
AAK1	   4541	   4558	   3204	  
AAPK1	   3080	   3234	   2996	  
AAPK2	   45	   110	   920	  
ABL1	   3091	   6331	   3448	  
ABL2	   4011	   6774	   8620	  
ACK1	   3095	   2893	   1522	  
ACV1B	   1329	   623	   957	  
ACV1C	   407	   74	   15	  
ACVL1	   1462	   14	   21	  
ACVR1	   1744	   2168	   761	  
ADCK1	   385	   506	   85	  
ADCK2	   997	   1868	   798	  
ADCK3	   1827	   3158	   1382	  
ADCK4	   727	   961	   486	  
ADCK5	   473	   428	   357	  
AKT1	   6143	   7598	   5622	  
AKT2	   3631	   4909	   4506	  
AKT3	   1652	   1077	   1741	  
ALK	   32	   9	   29	  
ALPK1	   1634	   2192	   127	  
ALPK2	   485	   425	   46	  
ALPK3	   445	   17	   6	  
AMHR2	   1	   0	   0	  
ANKK1	   19	   37	   1	  
ANPRA	   514	   178	   80	  
ANPRB	   414	   131	   198	  
ARAF	   1669	   2313	   1978	  
ARBK1	   3139	   2346	   1986	  
ARBK2	   2281	   1582	   321	  
ATM	   8329	   5312	   5142	  
ATR	   2603	   3571	   2306	  
AURKB	   1062	   744	   2294	  
AURKC	   35	   27	   7	  
AVR2A	   1203	   536	   493	  
AVR2B	   1380	   2305	   1580	  
BCR	   2766	   3889	   2364	  
BLK	   360	   30	   8	  
BMP2K	   2514	   1478	   1558	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BMPR2	   7307	   3749	   2949	  
BMR1A	   1325	   1514	   1250	  
BMR1B	   35	   602	   195	  
BMX	   23	   2	   2	  
BRAF1	   868	   874	   397	  
BRD2	   14255	   14120	   9924	  
BRD3	   1964	   2846	   1495	  
BRD4	   5737	   7065	   5209	  
BRDT	   1	   2	   1	  
BRSK1	   240	   772	   235	  
BRSK2	   13	   60	   65	  
BTK	   1719	   8	   4	  
BUB1	   1818	   3437	   4147	  
BUB1B	   1035	   2597	   2574	  
CAMKV	   5	   13	   0	  
CD11A	   1769	   2501	   1104	  
CD11B	   2296	   3368	   1822	  
CDC7	   685	   2044	   1005	  
CDK1	   835	   1207	   1838	  
CDK10	   1848	   3026	   2566	  
CDK12	   4159	   5605	   4990	  
CDK13	   3738	   3205	   2037	  
CDK14	   1523	   1914	   495	  
CDK15	   15	   19	   128	  
CDK16	   3015	   5628	   4515	  
CDK17	   1618	   2064	   1162	  
CDK18	   1031	   270	   58	  
CDK19	   2858	   2185	   800	  
CDK2	   1057	   2290	   2000	  
CDK20	   168	   164	   64	  
CDK3	   603	   416	   436	  
CDK4	   1501	   2985	   2435	  
CDK5	   395	   344	   474	  
CDK6	   10400	   5987	   4719	  
CDK7	   515	   1607	   976	  
CDK8	   541	   978	   471	  
CDK9	   1072	   1305	   1248	  
CDKL1	   163	   64	   273	  
CDKL2	   9	   12	   42	  
CDKL3	   233	   387	   270	  
CDKL4	   6	   1	   0	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CDKL5	   500	   349	   80	  
CHK1	   1150	   2193	   1944	  
CHK2	   926	   2370	   402	  
CLK1	   3514	   2896	   1239	  
CLK2	   1938	   1739	   1053	  
CLK3	   1791	   2235	   1364	  
CLK4	   1074	   1095	   576	  
CSF1R	   4810	   43	   67	  
CSK	   2977	   2397	   2468	  
CSK21	   2803	   5909	   3641	  
CSK22	   750	   1562	   879	  
CSKP	   3536	   2462	   2447	  
CTRO	   1917	   5713	   5231	  
DAPK1	   4903	   11	   435	  
DAPK2	   681	   67	   88	  
DAPK3	   1220	   1793	   1637	  
DCLK1	   757	   95	   161	  
DCLK2	   322	   636	   279	  
DCLK3	   8	   0	   0	  
DDR1	   6353	   1656	   1654	  
DDR2	   1438	   267	   26	  
DMPK	   1228	   2252	   1042	  
DUSTY	   1701	   2076	   928	  
DYR1A	   5217	   4176	   2312	  
DYR1B	   378	   130	   316	  
DYRK2	   3328	   1356	   1307	  
DYRK3	   327	   785	   599	  
DYRK4	   511	   618	   427	  
E2AK1	   3653	   7254	   3499	  
E2AK2	   2157	   1882	   1640	  
E2AK3	   1914	   1510	   512	  
E2AK4	   3958	   6128	   3827	  
EF2K	   1642	   3047	   1488	  
EGFR	   2533	   7941	   8970	  
EPHA1	   923	   11	   5	  
EPHA2	   578	   3639	   5197	  
EPHA3	   130	   400	   2	  
EPHA4	   1957	   496	   265	  
EPHA5	   0	   45	   59	  
EPHA6	   8	   61	   24	  
EPHA7	   98	   403	   12	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EPHA8	   2	   2	   0	  
EPHAA	   31	   13	   23	  
EPHB1	   592	   8	   13	  
EPHB2	   660	   1267	   2728	  
EPHB3	   3081	   46	   23	  
EPHB4	   2989	   4466	   1968	  
EPHB6	   358	   112	   4	  
ERBB2	   3025	   5535	   2554	  
ERBB3	   2830	   121	   182	  
ERBB4	   18	   68	   2	  
ERN1	   1210	   1088	   355	  
ERN2	   7	   3	   1	  
FAK1	   4375	   7923	   5783	  
FAK2	   3867	   2435	   213	  
FASTK	   1678	   1689	   1666	  
FER	   590	   952	   633	  
FES	   559	   13	   20	  
FGFR1	   2880	   5764	   4734	  
FGFR2	   5412	   12	   18	  
FGFR3	   288	   67	   67	  
FGFR4	   112	   25	   191	  
FGR	   1128	   3	   1	  
FLT3	   357	   2	   0	  
FRK	   645	   39	   30	  
FYN	   2736	   2318	   1578	  
GAK	   2981	   3423	   1986	  
GRK4	   169	   255	   208	  
GRK5	   904	   163	   531	  
GRK6	   1741	   2641	   1925	  
GRK7	   7	   1	   0	  
GSK3A	   1806	   2196	   2142	  
GSK3B	   3347	   5623	   2104	  
GUC2C	   42	   0	   14	  
GUC2D	   41	   3	   0	  
GUC2F	   0	   1	   0	  
HASP	   446	   479	   828	  
HCK	   1879	   25	   0	  
HIPK1	   7101	   6267	   3377	  
HIPK2	   5908	   20168	   7156	  
HIPK3	   5401	   3314	   1616	  
HIPK4	   10	   8	   6	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HSPB8	   298	   1791	   277	  
HUNK	   66	   11	   19	  
ICK	   2818	   1204	   2472	  
IGF1R	   2775	   3810	   2721	  
IKKA	   1088	   1559	   1511	  
IKKB	   2580	   5486	   1374	  
IKKE	   1339	   268	   1046	  
ILK	   2895	   3373	   3763	  
INSR	   3900	   5242	   1778	  
INSRR	   30	   1	   3	  
IRAK1	   3469	   8947	   6751	  
IRAK2	   333	   1265	   666	  
IRAK3	   1156	   35	   458	  
IRAK4	   1783	   1119	   525	  
ITK	   1637	   2	   7	  
JAK1	   7917	   6894	   3736	  
JAK2	   2534	   349	   245	  
JAK3	   3665	   13	   26	  
KALRN	   307	   39	   65	  
KAPCA	   2299	   1679	   1662	  
KAPCB	   3863	   1596	   923	  
KAPCG	   0	   0	   1	  
KC1A	   5431	   10369	   6174	  
KC1AL	   2	   3	   0	  
KC1D	   3054	   5599	   3604	  
KC1E	   3105	   6541	   3066	  
KC1G1	   2445	   2762	   1294	  
KC1G2	   2089	   2880	   2146	  
KC1G3	   1620	   4244	   1765	  
KCC1A	   404	   647	   861	  
KCC1B	   8	   3	   0	  
KCC1D	   506	   22	   171	  
KCC1G	   34	   2	   12	  
KCC2A	   60	   2	   3	  
KCC2B	   78	   33	   35	  
KCC2D	   2304	   4804	   1528	  
KCC2G	   1454	   1555	   2620	  
KCC4	   491	   264	   263	  
KGP1	   251	   590	   83	  
KGP2	   183	   96	   23	  
KIT	   471	   60	   2	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KKCC1	   226	   961	   339	  
KKCC2	   2602	   5983	   1604	  
KPCA	   788	   5152	   5089	  
KPCB	   2459	   0	   0	  
KPCD	   2316	   1573	   1714	  
KPCD1	   272	   640	   0	  
KPCD2	   3017	   1825	   1304	  
KPCD3	   3981	   3355	   2892	  
KPCE	   524	   657	   1282	  
KPCG	   28	   20	   21	  
KPCI	   2929	   2684	   1960	  
KPCL	   2509	   2064	   179	  
KPCT	   779	   2	   53	  
KPCZ	   1132	   157	   315	  
KPSH1	   964	   1297	   1031	  
KPSH2	   0	   0	   0	  
KS6A1	   2513	   2400	   1446	  
KS6A2	   1710	   3038	   646	  
KS6A3	   5220	   2928	   3202	  
KS6A4	   1527	   2447	   3338	  
KS6A5	   879	   424	   514	  
KS6A6	   13	   11	   36	  
KS6B1	   1916	   2832	   1718	  
KS6B2	   1215	   1314	   1377	  
KS6C1	   1709	   1427	   1046	  
KSR1	   1085	   341	   593	  
KSR2	   97	   2	   4	  
KSYK	   3186	   14	   11	  
LATS1	   2581	   3067	   1266	  
LATS2	   1675	   1414	   1464	  
LCK	   2059	   0	   6	  
LIMK1	   2590	   2539	   3279	  
LIMK2	   4788	   1498	   701	  
LMTK1	   66	   67	   6	  
LMTK2	   1416	   1593	   1415	  
LMTK3	   313	   22	   73	  
LRRK1	   2494	   2277	   1250	  
LRRK2	   2246	   421	   11	  
LTK	   111	   22	   83	  
LYN	   2288	   1711	   790	  
M3K1	   2917	   1111	   1295	  
	   109	  
M3K10	   543	   894	   528	  
M3K11	   2264	   1857	   1952	  
M3K12	   616	   963	   401	  
M3K13	   668	   142	   94	  
M3K14	   1291	   700	   1607	  
M3K15	   109	   147	   272	  
M3K2	   2424	   2253	   1105	  
M3K3	   2493	   1852	   2102	  
M3K4	   2250	   3350	   1855	  
M3K5	   1743	   779	   441	  
M3K6	   1224	   2002	   910	  
M3K7	   1688	   3076	   1531	  
M3K8	   1032	   353	   110	  
M3K9	   389	   886	   977	  
M3KL4	   961	   1214	   932	  
M4K1	   1515	   13	   4	  
M4K2	   1031	   600	   706	  
M4K3	   1208	   1098	   1406	  
M4K4	   9176	   11428	   10242	  
M4K5	   3352	   1394	   2843	  
MAK	   117	   71	   95	  
MAPK2	   3431	   3378	   2817	  
MAPK3	   1358	   2791	   2815	  
MAPK5	   948	   1177	   1069	  
MARK1	   194	   1244	   204	  
MARK2	   2705	   2799	   2076	  
MARK3	   3446	   5189	   2803	  
MARK4	   1562	   1610	   603	  
MAST1	   131	   231	   173	  
MAST2	   2760	   7563	   3035	  
MAST3	   1466	   1116	   677	  
MAST4	   962	   1251	   540	  
MASTL	   1996	   2324	   2060	  
MATK	   385	   6	   10	  
MELK	   1538	   3495	   2959	  
MERTK	   1132	   454	   1283	  
MET	   3406	   13476	   7486	  
MINK1	   5491	   3127	   3660	  
MK01	   4520	   4458	   3123	  
MK03	   1493	   800	   1039	  
MK04	   4	   3	   0	  
	   110	  
MK06	   2021	   2312	   1694	  
MK07	   749	   328	   687	  
MK08	   561	   1173	   1133	  
MK09	   1414	   3217	   2212	  
MK10	   141	   80	   1	  
MK11	   499	   451	   191	  
MK12	   688	   2719	   1337	  
MK13	   1504	   59	   1174	  
MK14	   3350	   2750	   4673	  
MK15	   245	   3	   11	  
MKNK1	   1847	   1109	   845	  
MKNK2	   2935	   8952	   2107	  
MLKL	   1089	   426	   1417	  
MLTK	   1730	   6233	   4571	  
MOK	   1128	   1382	   808	  
MOS	   0	   0	   0	  
MP2K1	   1736	   2321	   1854	  
MP2K2	   1391	   2516	   2141	  
MP2K3	   1241	   809	   2653	  
MP2K4	   1660	   853	   1595	  
MP2K5	   742	   1356	   503	  
MP2K6	   472	   3	   17	  
MP2K7	   1455	   2693	   2008	  
MRCKA	   3084	   14143	   5241	  
MRCKB	   4035	   6067	   4543	  
MRCKG	   799	   34	   95	  
MST4	   1442	   103	   737	  
MTOR	   3043	   5265	   3608	  
MUSK	   2	   5	   61	  
MYLK	   3818	   1702	   3679	  
MYLK2	   28	   4	   13	  
MYLK3	   25	   49	   7	  
MYLK4	   184	   31	   7	  
MYO3A	   14	   1	   1	  
MYO3B	   2	   11	   0	  
NEK1	   1473	   1855	   934	  
NEK10	   57	   63	   62	  
NEK11	   305	   134	   178	  
NEK2	   968	   1289	   1298	  
NEK3	   433	   503	   138	  
NEK4	   1325	   1576	   1558	  
	   111	  
NEK5	   55	   57	   38	  
NEK6	   2850	   3613	   3197	  
NEK7	   2366	   1435	   1829	  
NEK8	   269	   105	   275	  
NEK9	   3858	   5383	   2319	  
NIM1	   11	   14	   5	  
NLK	   762	   968	   845	  
NRBP	   3305	   3101	   2916	  
NRBP2	   2036	   2758	   876	  
NRK	   95	   5	   296	  
NTKL	   2499	   3422	   2856	  
NTRK1	   39	   4	   18	  
NTRK2	   950	   104	   6	  
NTRK3	   1075	   2	   10	  
NUAK1	   766	   543	   1443	  
NUAK2	   644	   271	   403	  
OBSCN	   1505	   149	   623	  
OXSR1	   2257	   4851	   4230	  
PACE1	   1112	   407	   397	  
PAK1	   2563	   3405	   1308	  
PAK2	   4189	   4097	   3628	  
PAK3	   29	   6	   0	  
PAK4	   1631	   1109	   2442	  
PAK6	   516	   80	   279	  
PAK7	   0	   2	   0	  
PAN3	   3051	   2711	   1698	  
PASK	   1646	   1421	   869	  
PDK1	   3329	   1668	   865	  
PDK1L	   1331	   875	   415	  
PDK2	   747	   857	   909	  
PDK3	   771	   62	   383	  
PDK4	   1442	   241	   79	  
PDPK1	   3038	   4228	   2371	  
PGFRA	   6688	   2101	   138	  
PGFRB	   5316	   1277	   217	  
PHKG1	   53	   38	   27	  
PHKG2	   801	   940	   725	  
PI3R4	   1422	   1977	   1435	  
PIM1	   2150	   1110	   1083	  
PIM2	   2236	   586	   335	  
PIM3	   1440	   1877	   1087	  
	   112	  
PINK1	   1158	   2558	   2024	  
PKDCC	   355	   184	   38	  
PKN1	   2988	   6505	   5342	  
PKN2	   3901	   4198	   3311	  
PKN3	   468	   391	   1733	  
PLK1	   1122	   1384	   2056	  
PLK2	   1577	   816	   2652	  
PLK3	   739	   1076	   506	  
PLK4	   544	   1623	   1378	  
PLK5	   1	   0	   0	  
PMYT1	   717	   2170	   1475	  
PRKDC	   11623	   25640	   17465	  
PRKX	   2763	   1745	   635	  
PRKY	   110	   80	   20	  
PRP4B	   5571	   3752	   4745	  
PRPK	   1110	   1014	   912	  
PTK6	   560	   51	   473	  
PTK7	   5347	   8252	   4088	  
PXK	   999	   3043	   1012	  
QSK	   2836	   1518	   2215	  
RAF1	   3518	   4765	   3360	  
RET	   76	   6	   0	  
RIOK1	   1508	   2040	   1322	  
RIOK2	   701	   1189	   976	  
RIOK3	   4052	   3762	   1948	  
RIPK1	   2613	   1437	   1823	  
RIPK2	   1264	   1117	   562	  
RIPK3	   770	   3	   0	  
RIPK4	   1039	   1583	   476	  
RK	   1	   0	   0	  
RN5A	   880	   486	   98	  
ROCK1	   4053	   3971	   2546	  
ROCK2	   3620	   3575	   3185	  
RON	   399	   18	   477	  
ROR1	   540	   976	   861	  
ROR2	   1005	   17	   7	  
ROS	   38	   2087	   1	  
RPKL1	   172	   10	   328	  
RYK	   1551	   2546	   1592	  
SBK1	   827	   28	   38	  
SBK2	   2	   0	   0	  
	   113	  
SCYL2	   2539	   2816	   1566	  
SG196	   525	   634	   509	  
SG223	   1114	   717	   1994	  
SG269	   4547	   3572	   2307	  
SGK1	   3450	   402	   725	  
SGK2	   74	   30	   9	  
SGK3	   1541	   503	   306	  
SGK71	   49	   29	   30	  
SIK1	   2044	   1455	   1157	  
SIK2	   1867	   2292	   1655	  
SLK	   4125	   5630	   4063	  
SMG1	   12447	   14972	   7621	  
SNRK	   3205	   1715	   1224	  
SPEG	   841	   1726	   394	  
SRC	   2632	   2077	   1514	  
SRMS	   5	   1	   3	  
SRPK1	   4656	   6787	   7311	  
SRPK2	   2590	   2751	   1547	  
SRPK3	   78	   37	   93	  
ST17A	   1547	   1061	   1074	  
ST17B	   5283	   1695	   1457	  
ST32A	   7	   185	   0	  
ST32B	   59	   8	   0	  
ST32C	   389	   1389	   974	  
ST38L	   2761	   1080	   909	  
STK10	   2760	   1368	   3302	  
STK11	   1168	   1896	   1449	  
STK16	   975	   1790	   1106	  
STK19	   878	   737	   573	  
STK24	   3887	   5906	   2845	  
STK25	   2935	   5621	   2902	  
STK3	   1058	   1346	   631	  
STK31	   27	   17	   39	  
STK33	   18	   0	   420	  
STK35	   2013	   2917	   2447	  
STK36	   1525	   1343	   1144	  
STK38	   4182	   1892	   3684	  
STK39	   1129	   1662	   1051	  
STK4	   6406	   4400	   4461	  
STK40	   3199	   3243	   4459	  
STK6	   1106	   1839	   5061	  
	   114	  
STRAA	   1185	   1585	   892	  
STYK1	   52	   4	   162	  
TAF1	   3778	   4309	   2488	  
TAF1L	   38	   76	   27	  
TAOK1	   3711	   4053	   2640	  
TAOK2	   2247	   2966	   2077	  
TAOK3	   4552	   1649	   3225	  
TBCK	   1229	   981	   343	  
TBK1	   1104	   1217	   934	  
TEC	   191	   442	   321	  
TESK1	   1295	   1158	   640	  
TESK2	   700	   254	   156	  
TEX14	   71	   18	   14	  
TGFR1	   4518	   3164	   3469	  
TGFR2	   5126	   5628	   5836	  
TIE1	   670	   18	   315	  
TIE2	   542	   9	   4	  
TIF1A	   1775	   1796	   1430	  
TIF1B	   5037	   6196	   6856	  
TITIN	   5365	   794	   800	  
TLK1	   4915	   3674	   2304	  
TLK2	   2536	   2943	   1946	  
TNI3K	   53	   180	   18	  
TNIK	   1178	   188	   384	  
TNK1	   670	   122	   178	  
TOPK	   426	   1211	   1272	  
TRI33	   4881	   3965	   3292	  
TRIB1	   3262	   1185	   630	  
TRIB2	   1326	   578	   1583	  
TRIB3	   285	   5057	   1124	  
TRIO	   3965	   14130	   11784	  
TRPM6	   68	   5	   7	  
TRPM7	   4781	   4924	   2189	  
TRRAP	   9223	   6967	   7483	  
TSSK1	   3	   9	   1	  
TSSK2	   13	   33	   17	  
TSSK3	   192	   204	   107	  
TSSK4	   236	   126	   111	  
TSSK6	   97	   93	   85	  
TTBK1	   25	   1	   9	  
TTBK2	   1052	   2868	   648	  
	   115	  
TTK	   1383	   1481	   1432	  
TXK	   273	   12	   49	  
TYK2	   3394	   3299	   2996	  
TYRO3	   409	   2405	   1038	  
UFO	   3553	   6231	   13023	  
UHMK1	   2645	   2551	   2132	  
ULK1	   1525	   2795	   740	  
ULK2	   736	   1178	   277	  
ULK3	   1383	   1707	   793	  
ULK4	   514	   299	   373	  
VGFR1	   1555	   15	   8	  
VGFR2	   1584	   401	   184	  
VGFR3	   700	   17	   2	  
VRK1	   785	   903	   1035	  
VRK2	   1565	   1977	   730	  
VRK3	   1271	   1044	   817	  
WEE1	   1682	   3225	   1726	  
WEE2	   17	   2	   0	  
WNK1	   13040	   14872	   9712	  
WNK2	   1370	   38	   4	  
WNK3	   62	   8	   420	  
WNK4	   55	   343	   326	  
YES	   3395	   4472	   2658	  
YSK4	   10	   4	   0	  
ZAP70	   2136	   4	   2	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APPENDIX 4: RNA-seq RPKM values for expressed kinases in TNBC with greater 
than 50 reads 
 
gene	   Patient	  18	   SUM159	   MDA-­‐MB-­‐231	  
AAK1	   29.7279423	   27.55911908	   25.24687015	  
AAPK1	   25.09224835	   24.33360978	   29.37868558	  
AAPK2	   0	   0.451205459	   4.918056525	  
ABL1	   22.83468583	   43.19624664	   30.65949409	  
ABL2	   18.74031818	   29.23123427	   48.47672316	  
ACK1	   35.95904024	   31.04370409	   21.28451616	  
ACV1B	   17.44605376	   7.553320887	   15.12118598	  
ACV1C	   1.949830325	   0.327424968	   0	  
ACVL1	   15.27207183	   0	   0	  
ACVR1	   24.46929072	   28.09388764	   12.85171981	  
ADCK1	   9.033400419	   10.96525439	   2.400552172	  
ADCK2	   18.57404261	   32.14147582	   17.8943473	  
ADCK3	   28.75377467	   45.90353235	   26.1797836	  
ADCK4	   13.87634706	   16.9411073	   11.16551356	  
ADCK5	   12.40952601	   10.37087704	   11.27363476	  
AKT1	   93.84117236	   107.1987847	   103.3726006	  
AKT2	   36.03407842	   44.99433791	   53.8245056	  
AKT3	   28.95926586	   17.43696402	   36.73482435	  
ALPK1	   19.47102759	   24.12431734	   1.821554763	  
ALPK2	   3.609843074	   2.921549018	   0	  
ALPK3	   2.221927107	   0	   0	  
ANPRA	   6.55321715	   2.095989514	   1.227674171	  
ANPRB	   5.0636452	   1.479830198	   2.914941267	  
ARAF	   47.36530711	   60.62577685	   67.56658976	  
ARBK1	   52.42369886	   36.18611969	   39.92245869	  
ARBK2	   17.48810266	   11.20215431	   2.962266537	  
ATM	   83.55094193	   49.21462924	   62.0857958	  
ATR	   15.93976606	   20.1964616	   16.99686283	  
AURKB	   37.06573661	   23.98273547	   96.37030282	  
AVR2A	   9.524343509	   3.919330398	   4.69805432	  
AVR2B	   5.031257037	   7.76150625	   6.933558709	  
BCR	   25.05183337	   32.53141431	   25.77131043	  
BLK	   7.156991616	   0	   0	  
BMP2K	   44.34396966	   24.07805445	   33.07793885	  
BMPR2	   37.18282183	   17.61961205	   18.06257662	  
BMR1A	   20.54142664	   21.67795262	   23.32525654	  
BMR1B	   0	   4.248090432	   1.793312195	  
BRAF1	   12.24735168	   11.38968096	   6.742402295	  
	   117	  
BRD2	   49.7007865	   45.46826678	   41.64707326	  
BRD3	   19.94191062	   26.6893404	   18.27124605	  
BRD4	   64.08061373	   72.88390642	   70.03221485	  
BRSK1	   3.683202226	   10.94231685	   4.340940933	  
BRSK2	   0	   0.721223599	   1.018253857	  
BTK	   48.41495589	   0	   0	  
BUB1	   24.55868726	   42.88135153	   67.42904312	  
BUB1B	   15.98304042	   37.03980237	   47.84419835	  
CD11A	   45.21376455	   59.03834713	   33.96359085	  
CD11B	   54.96919129	   74.47271892	   52.50462102	  
CDC7	   9.600140961	   26.45730433	   16.95332126	  
CDK1	   19.03450235	   25.41206657	   50.43154229	  
CDK10	   52.29671977	   79.08954356	   87.40390292	  
CDK12	   24.79783132	   30.86583719	   35.81187156	  
CDK13	   39.16452842	   31.01410847	   25.68894832	  
CDK14	   23.06951583	   26.77676907	   9.024963769	  
CDK15	   0	   0	   4.354143647	  
CDK16	   43.49095591	   74.97964652	   78.39188057	  
CDK17	   23.20481582	   27.33927317	   20.05891454	  
CDK18	   19.04628956	   4.606734089	   1.28967833	  
CDK19	   24.8945465	   17.57806634	   8.387522018	  
CDK2	   19.81158622	   39.64216884	   45.12071248	  
CDK20	   3.041650072	   2.742341136	   1.394702671	  
CDK3	   10.21612471	   6.509383627	   8.891131927	  
CDK4	   48.44095735	   88.9721374	   94.58726814	  
CDK5	   18.69844351	   15.0398833	   27.00774933	  
CDK6	   37.0483731	   19.69802678	   20.23426676	  
CDK7	   15.24662136	   43.93998718	   34.77906444	  
CDK8	   12.86587072	   21.48119491	   13.48231646	  
CDK9	   18.04444609	   20.28789294	   25.2851216	  
CDKL1	   3.262348488	   1.183042601	   6.576685668	  
CDKL3	   6.342206251	   9.729108986	   8.846060312	  
CDKL5	   6.06205624	   3.907986428	   1.167458994	  
CHK1	   22.30605605	   39.28631039	   45.38610369	  
CHK2	   22.63753002	   53.51112253	   11.82893913	  
CLK1	   70.76175761	   53.86083413	   30.03100403	  
CLK2	   38.45956405	   31.87335863	   25.15247043	  
CLK3	   29.19482011	   33.64847671	   26.7624753	  
CLK4	   19.62708604	   18.48176004	   12.66997389	  
CSF1R	   70.60163874	   0	   1.183712407	  
CSK	   58.86792594	   43.77695976	   58.74173194	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CSK21	   43.18130365	   84.07450226	   67.51418389	  
CSK22	   18.64245252	   35.85918997	   26.29858301	  
CSKP	   18.39849912	   11.83139222	   15.32518765	  
CTRO	   9.276946914	   25.53435227	   30.46978362	  
DAPK1	   46.44061111	   0	   4.959375375	  
DAPK2	   12.04265988	   1.094278269	   1.873094431	  
DAPK3	   23.8217475	   32.33491614	   38.47371798	  
DCLK1	   4.864669529	   0.563843699	   1.245331664	  
DCLK2	   3.679364328	   6.711996176	   3.837274049	  
DDR1	   28.37326528	   6.830751069	   8.891349054	  
DDR2	   18.62861578	   3.194556869	   0	  
DMPK	   18.4465789	   31.24377605	   18.84025937	  
DUSTY	   12.6684324	   14.27984774	   8.318944606	  
DYR1A	   58.13927424	   42.98202995	   31.01260807	  
DYR1B	   7.638932795	   2.426397248	   7.686518266	  
DYRK2	   22.75913009	   8.564651444	   10.75844787	  
DYRK3	   6.312923741	   13.99684361	   13.91910479	  
DYRK4	   15.92114303	   17.78359183	   16.01337633	  
E2AK1	   50.07450571	   91.83795681	   57.73147224	  
E2AK2	   38.80693136	   31.27205631	   35.51441759	  
E2AK3	   17.44992376	   12.71470272	   5.618537098	  
E2AK4	   44.19092117	   63.19077539	   51.4301059	  
EF2K	   12.09694485	   20.73254732	   13.19493243	  
EGFR	   44.87122209	   129.9228585	   191.2611852	  
EPHA1	   11.39981822	   0	   0	  
EPHA2	   8.598696257	   49.99936494	   93.0591707	  
EPHA3	   1.135531598	   3.226959582	   0	  
EPHA4	   18.08063948	   4.232357069	   2.946934793	  
EPHA5	   0	   0	   0.407973969	  
EPHA6	   0	   1.246446561	   0	  
EPHA7	   0.747666941	   2.839649981	   0	  
EPHB1	   8.785766487	   0	   0	  
EPHB2	   5.971421975	   10.58737033	   29.7084425	  
EPHB3	   30.27875965	   0	   0	  
EPHB4	   39.20731969	   54.10502731	   31.0719153	  
EPHB6	   4.842096346	   1.399091395	   0	  
ERBB2	   32.27128442	   54.53636155	   32.79543958	  
ERBB3	   39.27955232	   1.551111891	   3.040557168	  
ERBB4	   0	   0.20782275	   0	  
ERN1	   12.57129697	   10.44001864	   4.439404932	  
FAK1	   48.06718766	   80.39665403	   76.47606601	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FAK2	   53.67612685	   31.21645822	   3.558674722	  
FASTK	   37.49812184	   34.85979846	   44.81199182	  
FER	   13.0265695	   19.41300027	   16.82222552	  
FES	   9.075288453	   0	   0	  
FGFR1	   27.54470165	   50.91517257	   54.49736824	  
FGFR2	   81.84287265	   0	   0	  
FGFR3	   4.012388425	   0.862110524	   1.123535956	  
FGFR4	   2.18735443	   0	   4.489895117	  
FGR	   20.98543689	   0	   0	  
FLT3	   3.862055704	   0	   0	  
FRK	   9.370956827	   0	   0	  
FYN	   59.83645235	   46.82101651	   41.53922925	  
GAK	   43.66619071	   46.30926555	   35.01581724	  
GRK4	   3.218933549	   4.485833503	   4.768593837	  
GRK5	   17.9519878	   2.989574507	   12.69229994	  
GRK6	   34.57483831	   48.44036991	   46.01440515	  
GSK3A	   29.73001859	   33.38777157	   42.44226892	  
GSK3B	   21.63114411	   33.56367637	   16.36708	  
HASP	   6.634980157	   6.581394836	   14.82643705	  
HCK	   37.0077802	   0	   0	  
HIPK1	   45.25536584	   36.88823918	   25.90498348	  
HIPK2	   16.27215677	   51.30327963	   23.72338498	  
HIPK3	   61.42408247	   34.80925013	   22.12114225	  
HSPB8	   6.210751967	   34.47475356	   6.948793121	  
HUNK	   0.371869596	   0	   0	  
ICK	   24.87593179	   9.816180112	   26.26567259	  
IGF1R	   21.96204018	   27.84917492	   25.92029426	  
IKKA	   12.79220966	   16.92935654	   21.38369884	  
IKKB	   32.53733449	   63.89924581	   20.85694473	  
IKKE	   19.94299005	   3.686567182	   18.75180472	  
ILK	   75.94575506	   81.72387304	   118.8203551	  
INSR	   23.00521984	   28.55857019	   12.62394893	  
IRAK1	   54.37949463	   129.5346535	   127.3798306	  
IRAK2	   3.994267712	   14.01396811	   9.61543324	  
IRAK3	   7.97608449	   0	   3.803637156	  
IRAK4	   17.44428593	   10.11136069	   6.182481824	  
ITK	   15.60135015	   0	   0	  
JAK1	   71.77428097	   57.72409698	   40.76775202	  
JAK2	   20.6987875	   2.632942564	   2.408829556	  
JAK3	   51.39195307	   0	   0	  
KALRN	   2.97944501	   0	   0.759297635	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KAPCA	   50.16323247	   33.83567947	   43.64949806	  
KAPCB	   47.75269731	   18.22148424	   13.73335328	  
KC1A	   79.05327224	   139.3973719	   108.1703824	  
KC1D	   67.57157839	   114.4150518	   95.98016778	  
KC1E	   64.59541642	   125.6787666	   76.7739596	  
KC1G1	   26.54799398	   27.69836822	   16.91176032	  
KC1G2	   26.4525849	   33.68215171	   32.7085345	  
KC1G3	   16.12083631	   39.00547687	   21.14068012	  
KCC1A	   11.29226697	   16.70250905	   28.96707308	  
KCC1D	   10.60954232	   0	   4.31562733	  
KCC2A	   0.797634902	   0	   0	  
KCC2B	   0.80670513	   0	   0	  
KCC2D	   21.6248941	   41.64397493	   17.26221655	  
KCC2G	   22.18649792	   21.91454233	   48.1201898	  
KCC4	   9.915305717	   4.923865793	   6.392666632	  
KGP1	   4.0845125	   8.867397614	   1.625722034	  
KGP2	   2.59464063	   1.257115036	   0	  
KIT	   7.102115727	   0.835594843	   0	  
KKCC1	   2.924385699	   11.48490119	   5.279923157	  
KKCC2	   25.42939113	   54.00392624	   18.86838482	  
KPCA	   5.677687234	   34.28457458	   44.13461982	  
KPCB	   19.08044326	   0	   0	  
KPCD	   52.92073231	   33.19660538	   47.14110946	  
KPCD1	   3.076354307	   6.685364413	   0	  
KPCD2	   52.66626791	   29.42373264	   27.39911384	  
KPCD3	   38.43964117	   29.91970691	   33.61144064	  
KPCE	   6.671853095	   7.726062566	   19.64739176	  
KPCI	   28.56235185	   24.17323465	   23.00553599	  
KPCL	   37.47958164	   28.47616031	   3.218465038	  
KPCT	   10.06463212	   0	   0.824210245	  
KPCZ	   24.71435323	   3.165775678	   8.277802646	  
KPSH1	   15.99999828	   19.8820216	   20.59696632	  
KS6A1	   35.91352332	   31.67775751	   24.87342038	  
KS6A2	   13.05120994	   21.41509957	   5.934564781	  
KS6A3	   27.62425091	   14.31095916	   20.39590715	  
KS6A4	   21.35457411	   31.60556146	   56.18752486	  
KS6A5	   12.83676392	   5.718869662	   9.035069333	  
KS6B1	   17.64926508	   24.09361872	   19.04828903	  
KS6B2	   30.47383614	   30.43854426	   41.57061809	  
KS6C1	   21.80737028	   16.81755556	   16.06551349	  
KSR1	   14.36499977	   4.169729934	   9.450010047	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KSR2	   0.237309827	   0	   0	  
KSYK	   29.91859931	   0	   0	  
LATS1	   29.04302325	   31.87463769	   17.14704214	  
LATS2	   12.64797623	   9.861280261	   13.3060453	  
LCK	   42.99653486	   0	   0	  
LIMK1	   32.86164993	   29.75294536	   50.07635493	  
LIMK2	   59.98448211	   17.3330204	   10.57071786	  
LMTK1	   0.657471143	   0.616432072	   0	  
LMTK2	   10.5176178	   10.92817322	   12.65063318	  
LMTK3	   2.619452054	   0	   0.735344194	  
LRRK1	   19.07071916	   16.08093569	   11.50488617	  
LRRK2	   13.66415041	   2.365552772	   0	  
LTK	   1.667854075	   0	   1.501118079	  
LYN	   30.96554719	   21.38702668	   12.86919915	  
M3K1	   16.13616537	   5.67617307	   8.622542961	  
M3K10	   7.968331878	   12.11665567	   9.326167226	  
M3K11	   37.12875591	   28.12700832	   38.53146128	  
M3K12	   7.507830019	   10.84020935	   5.882741749	  
M3K13	   9.469265033	   1.859113126	   1.603870704	  
M3K14	   13.22463089	   6.622668548	   19.8141244	  
M3K15	   1.26701322	   1.578154966	   3.80561845	  
M3K2	   34.31281802	   29.45524411	   18.82728692	  
M3K3	   21.89550737	   15.02281711	   22.22118105	  
M3K4	   20.96135538	   28.8243361	   20.80091544	  
M3K5	   20.37108346	   8.40875815	   6.20378905	  
M3K6	   15.03559843	   22.7133418	   13.45495916	  
M3K7	   25.72994447	   43.30423798	   28.08945344	  
M3K8	   15.19514245	   4.80040022	   1.949483013	  
M3K9	   3.052285898	   6.420768235	   9.227241008	  
M3KL4	   8.741000982	   10.19844906	   10.20364605	  
M4K1	   30.62007546	   0	   0	  
M4K2	   21.57940775	   11.59871212	   17.78636697	  
M4K3	   13.00737285	   10.91949762	   18.22257167	  
M4K4	   62.17517032	   71.51735983	   83.53145413	  
M4K5	   42.64360343	   16.37911087	   43.53398639	  
MAK	   1.384159167	   0.77577572	   1.352774688	  
MAPK2	   42.75003812	   38.87345096	   42.2478222	  
MAPK3	   21.64163829	   41.07975679	   53.99710236	  
MAPK5	   20.14618816	   23.10141992	   27.34411962	  
MARK1	   1.706623907	   10.10727631	   2.160070641	  
MARK2	   30.84300175	   29.47609384	   28.49170308	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MARK3	   49.56945204	   68.93823794	   48.53149102	  
MARK4	   21.06116273	   20.04956033	   9.786340403	  
MAST1	   1.987446759	   3.236784984	   3.159162768	  
MAST2	   32.44820633	   82.12083873	   42.94790659	  
MAST3	   10.3512969	   7.277842497	   5.753752216	  
MAST4	   13.19905555	   15.85268235	   8.917913101	  
MASTL	   23.09285924	   24.83310119	   28.68706274	  
MATK	   7.68245165	   0	   0	  
MELK	   27.86194841	   58.47631426	   64.52110624	  
MERTK	   13.41568441	   4.96935385	   18.30184001	  
MET	   50.34463486	   183.9700884	   133.186457	  
MINK1	   46.89339624	   24.66412928	   37.6220989	  
MK01	   65.49401935	   59.65968227	   54.4674301	  
MK03	   31.1917965	   15.43647846	   26.12749782	  
MK06	   19.90383837	   21.02984228	   20.08101314	  
MK07	   10.5477132	   4.266070237	   11.64487747	  
MK08	   12.28681025	   23.72749908	   29.86812027	  
MK09	   8.948966995	   18.80408566	   16.85040374	  
MK10	   2.629862247	   1.378102555	   0	  
MK11	   11.9124309	   9.943838308	   5.48826291	  
MK12	   9.796799737	   35.75877749	   22.91547643	  
MK13	   34.54671315	   1.251666337	   32.45851795	  
MK14	   32.33284144	   24.51373135	   54.28708695	  
MK15	   5.354222026	   0	   0	  
MKNK1	   37.08478683	   20.5654445	   20.42148369	  
MKNK2	   41.93860408	   118.141805	   36.23865684	  
MLKL	   20.50372848	   7.407850762	   32.11267649	  
MLTK	   15.47337184	   51.48890418	   49.20981948	  
MOK	   27.57293473	   31.20035958	   23.77316176	  
MP2K1	   30.74478834	   37.9642295	   39.52148076	  
MP2K2	   32.79288729	   54.78237117	   60.7534416	  
MP2K3	   21.93004797	   13.20364943	   56.4295701	  
MP2K4	   19.20014557	   9.112197572	   22.20541082	  
MP2K5	   17.82425819	   30.08464642	   14.54377797	  
MP2K6	   9.112232433	   0	   0	  
MP2K7	   24.45172985	   41.79849185	   40.61738838	  
MRCKA	   16.66208083	   70.57226754	   34.08244313	  
MRCKB	   39.71993483	   55.15903329	   53.82814536	  
MRCKG	   6.723226142	   0	   0.962179804	  
MST4	   18.7340932	   1.235897074	   11.52488487	  
MTOR	   19.85714579	   31.73152252	   28.33890677	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MUSK	   0	   0	   1.770743881	  
MYLK	   32.79609449	   13.50278721	   38.0380009	  
MYLK4	   1.455142363	   0	   0	  
NEK1	   12.11692829	   14.09325688	   9.247798509	  
NEK10	   1.160213956	   1.184353757	   1.518995931	  
NEK11	   5.185093961	   2.103968594	   3.642323244	  
NEK2	   22.11581908	   27.19933285	   35.69472622	  
NEK3	   7.346126599	   7.881632123	   2.818066842	  
NEK4	   17.01991843	   18.69715258	   24.08855456	  
NEK5	   1.033670945	   0.989400529	   0	  
NEK6	   45.834206	   53.66491885	   61.88553933	  
NEK7	   23.81450199	   13.3400153	   22.15859199	  
NEK8	   3.916402252	   1.411893613	   4.819138378	  
NEK9	   33.95090645	   43.75132333	   24.56357592	  
NLK	   11.28355337	   13.23865719	   15.06084422	  
NRBP	   54.23282977	   46.99701028	   57.59436748	  
NRBP2	   25.6555601	   32.09782846	   13.28646735	  
NRK	   0.693418132	   0	   2.600548701	  
NTKL	   42.48839899	   53.73555995	   58.44723967	  
NTRK2	   5.830494395	   0.589512175	   0	  
NTRK3	   16.28093303	   0	   0	  
NUAK1	   4.672808208	   3.059332491	   10.59539639	  
NUAK2	   12.46363274	   4.844017796	   9.387836425	  
OBSCN	   6.812134666	   0.622888993	   3.394192449	  
OXSR1	   26.24264146	   52.09366652	   59.19950111	  
PACE1	   14.09926682	   4.766107288	   6.058762663	  
PAK1	   35.7345906	   43.84650525	   21.95076398	  
PAK2	   28.39291374	   25.64739318	   29.598423	  
PAK4	   25.56151978	   16.05247195	   46.06595317	  
PAK6	   5.797887309	   0.830209538	   3.773340205	  
PAN3	   28.97454519	   23.77834372	   19.4094754	  
PASK	   15.23305342	   12.1458769	   9.680072327	  
PDK1	   49.68419547	   22.99207545	   15.53897134	  
PDK1L	   13.02717159	   7.90965961	   4.889020591	  
PDK2	   13.21821631	   14.00589086	   19.36055611	  
PDK3	   17.37409941	   1.29037897	   10.38839345	  
PDK4	   17.86292162	   2.757286775	   1.177920595	  
PDPK1	   23.41667929	   30.09886923	   21.99737122	  
PGFRA	   77.21268141	   22.40247935	   1.917666794	  
PGFRB	   71.2486361	   15.80738908	   3.500684795	  
PHKG1	   1.654161089	   0	   0	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PHKG2	   23.99105502	   26.00293361	   26.13704759	  
PI3R4	   11.6520982	   14.96197318	   14.15331368	  
PIM1	   37.59672249	   17.92718783	   22.7951091	  
PIM2	   41.64720556	   10.0806688	   7.51035673	  
PIM3	   31.86297996	   38.35887256	   28.95043768	  
PINK1	   22.21499621	   45.3227118	   46.7358218	  
PKDCC	   5.86870627	   2.809373662	   0	  
PKN1	   50.97603225	   102.4968219	   109.6960554	  
PKN2	   30.98309423	   30.79420062	   31.65262335	  
PKN3	   6.033292932	   4.655464071	   26.8911152	  
PLK1	   21.18256281	   24.13233797	   46.72081905	  
PLK2	   35.18439545	   16.81458766	   71.21862935	  
PLK3	   14.71984492	   19.79469117	   12.13140228	  
PLK4	   6.05775602	   16.69202633	   18.46986781	  
PMYT1	   14.89164	   41.62562523	   36.87373114	  
PRKDC	   47.61255824	   97.00608174	   86.11395992	  
PRKX	   18.99046961	   11.07714686	   5.253276213	  
PRKY	   0.63429808	   0.426057644	   0	  
PRP4B	   52.64399408	   32.74584229	   53.97014457	  
PRPK	   14.07283637	   11.87337754	   13.91730642	  
PTK6	   10.97448452	   0.923089779	   11.1572955	  
PTK7	   63.24466989	   90.14686506	   58.2004476	  
PXK	   21.39389814	   60.18718767	   26.08594892	  
QSK	   23.69039977	   11.71158291	   22.27109574	  
RAF1	   49.39836388	   61.79556364	   56.78814711	  
RET	   0.719644202	   0	   0	  
RIOK1	   35.7605304	   44.67971977	   37.73425299	  
RIOK2	   9.378963915	   14.69252251	   15.71767687	  
RIOK3	   45.66726266	   39.15903653	   26.42568098	  
RIPK1	   27.20346524	   13.81717476	   22.84405407	  
RIPK2	   20.96252766	   17.1091097	   11.21849456	  
RIPK3	   16.80637044	   0	   0	  
RIPK4	   11.11381549	   15.63890036	   6.128529472	  
RN5A	   10.24459944	   5.225480633	   1.373219865	  
ROCK1	   25.36017198	   22.94843855	   19.17501364	  
ROCK2	   23.53195338	   21.46362727	   24.92071721	  
RON	   6.40894486	   0	   9.22218245	  
ROR1	   7.904793378	   13.19545115	   15.17055976	  
ROR2	   14.373741	   0	   0	  
ROS	   0	   11.40074538	   0	  
RPKL1	   2.915714207	   0	   6.692556425	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RYK	   21.97005573	   33.30852667	   27.14339181	  
SBK1	   6.868549298	   0	   0	  
SCYL2	   40.1396935	   41.11702316	   29.7992134	  
SG196	   13.52645565	   15.08660884	   15.78498535	  
SG223	   10.01804383	   5.95517537	   21.5836347	  
SG269	   20.6505633	   14.98290624	   12.61119482	  
SGK1	   54.22991851	   5.836111396	   13.71701315	  
SGK2	   1.76671772	   0	   0	  
SGK3	   15.1299998	   4.561229576	   3.616257952	  
SIK1	   18.07283171	   11.8819021	   12.31346736	  
SIK2	   13.64344647	   15.46934943	   14.5572541	  
SLK	   30.80973979	   38.83739888	   36.52688114	  
SMG1	   45.24891646	   50.2690845	   33.34702903	  
SNRK	   30.28979347	   14.96959551	   13.92359517	  
SPEG	   7.560542582	   14.33096457	   4.263388224	  
SRC	   26.74744145	   19.49442905	   18.51927272	  
SRPK1	   44.05091996	   59.30584842	   83.25694796	  
SRPK2	   38.46448031	   37.73361018	   27.65362761	  
SRPK3	   1.336178022	   0	   1.917583841	  
ST17A	   16.30048085	   10.32531118	   13.62122213	  
ST17B	   41.36721625	   12.25809694	   13.73209911	  
ST32A	   0	   4.487690646	   0	  
ST32B	   0.748699996	   0	   0	  
ST32C	   9.022448227	   29.75464041	   27.19164275	  
ST38L	   24.19957937	   8.7426447	   9.589743372	  
STK10	   19.01696856	   8.705545041	   27.38488786	  
STK11	   14.79014799	   22.17408321	   22.08511952	  
STK16	   16.1255997	   27.34273497	   22.01750367	  
STK19	   4.011651777	   3.110096489	   3.151265723	  
STK24	   35.33967036	   49.5928491	   31.13378455	  
STK25	   54.43715245	   96.28941371	   64.78677974	  
STK3	   18.82143282	   22.11514225	   13.51132887	  
STK33	   0	   0	   9.32690341	  
STK35	   19.27013132	   25.79021671	   28.19528964	  
STK36	   17.95054594	   14.60029039	   16.20822787	  
STK38	   47.31180744	   19.76898201	   50.16569394	  
STK39	   14.28760283	   19.42558514	   16.00920754	  
STK4	   52.13502822	   33.07295639	   43.69951263	  
STK40	   34.42921808	   32.23573161	   57.76331158	  
STK6	   20.73104172	   31.83650543	   114.1836778	  
STRAA	   21.57365871	   26.65093091	   19.54663484	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STYK1	   0.71598862	   0	   2.684846631	  
TAF1	   48.00220048	   50.56538869	   38.04970205	  
TAF1L	   0	   0.469869749	   0	  
TAOK1	   32.45878174	   32.74127051	   27.7937329	  
TAOK2	   21.68109793	   26.43181636	   24.12217072	  
TAOK3	   46.23948996	   15.47066921	   39.43139957	  
TBCK	   15.22738467	   11.22587253	   5.115278073	  
TBK1	   15.40489244	   15.68403628	   15.68693744	  
TEC	   2.195442326	   4.692330546	   4.441149465	  
TESK1	   22.23891476	   18.36665399	   13.22895342	  
TESK2	   11.36351741	   3.80825588	   3.048182964	  
TEX14	   0.565228246	   0	   0	  
TGFR1	   38.59053111	   24.96023483	   35.66485975	  
TGFR2	   45.70719477	   46.3487171	   62.63584498	  
TIE1	   11.54874449	   0	   6.535400629	  
TIE2	   7.193810235	   0	   0	  
TIF1A	   18.66978473	   17.44716822	   18.10417263	  
TIF1B	   86.76252455	   98.57103156	   142.1453738	  
TITIN	   8.30510711	   1.135203384	   1.490620845	  
TLK1	   44.90348536	   31.00083165	   25.33615434	  
TLK2	   19.67315027	   21.08592149	   18.17059663	  
TNI3K	   0.68755341	   2.156655311	   0	  
TNIK	   10.6269938	   1.566392695	   4.169635125	  
TNK1	   11.32013773	   1.903769663	   3.619916911	  
TOPK	   8.977381827	   23.570126	   32.26479431	  
TRI33	   30.75660806	   23.07546627	   24.96842504	  
TRIB1	   45.92770248	   15.4094372	   10.6766008	  
TRIB2	   15.23113845	   6.131889829	   21.88625466	  
TRIB3	   4.92988439	   80.79090843	   23.40237195	  
TRIO	   24.05287318	   79.16689188	   86.04352522	  
TRPM6	   0.536179136	   0	   0	  
TRPM7	   46.22952193	   43.97403988	   25.47698971	  
TRRAP	   38.0185359	   26.52446623	   37.12791971	  
TSSK3	   6.006850507	   5.894587591	   4.02931355	  
TSSK4	   7.998329588	   3.943987242	   4.528057817	  
TSSK6	   2.728982786	   2.416515992	   2.878390279	  
TTBK2	   11.73792898	   29.55510779	   8.702668384	  
TTK	   19.31416896	   19.10233987	   24.07124514	  
TXK	   5.881950784	   0	   0	  
TYK2	   38.58232875	   34.63670556	   40.9939814	  
TYRO3	   6.186285423	   33.59691413	   18.89755816	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UFO	   39.10081108	   63.33240392	   172.5056368	  
UHMK1	   39.63685297	   35.3070645	   38.455847	  
ULK1	   12.11207862	   20.50257045	   7.074280059	  
ULK2	   4.67949059	   6.917413187	   2.119835811	  
ULK3	   26.52832381	   30.24118563	   18.3089108	  
ULK4	   8.630958988	   4.637082102	   7.538873522	  
VGFR1	   19.8167464	   0	   0	  
VGFR2	   15.29119956	   3.57526646	   2.137991103	  
VGFR3	   10.46791296	   0	   0	  
VRK1	   18.99058949	   20.17595973	   30.13775031	  
VRK2	   31.37914857	   36.61096244	   17.61778741	  
VRK3	   28.32686212	   21.48973598	   21.91677586	  
WEE1	   17.90736273	   31.71122517	   22.11811553	  
WNK1	   119.3150694	   125.6795875	   106.9616447	  
WNK2	   11.6256689	   0	   0	  
WNK3	   0.336856715	   0	   2.74665746	  
WNK4	   0.740870014	   4.26727971	   5.285652644	  
YES	   30.33733361	   36.90770891	   28.58869273	  
ZAP70	   38.82020608	   0	   0	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